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vABSTRACT
Candida species are opportunistic yeasts that cause infections in immunocompromised
individuals such as HIV and cancer patients. Recent studies show that 5-fluorouracil, a
nucleoside analogue used for cancer treatment, increases Candida cell virulence. The aim
of this study is to determine the effects of commonly used anti-HIV nucleoside analogue
drugs on the virulence of Candida albicans, the predominant species associated with oral
candidiasis.
Oral swabs were collected from antiretroviral-naïve HIV-positive individuals. C. albicans
was characterised from 39 of these swabs using standard microbiological techniques and
polymerase chain reaction. The effect of nucleoside reverse transcriptase inhibitors
(NRTIs) zidovudine, stavudine, didanosine and lamivudine, at predicted drug peak
concentrations in patients, as well as half and double these concentrations on select
virulence factors of C. albicans isolates were studied. In addition, antifungal susceptibility
to amphotericin B was assessed. Not all 39 isolates were used in the assays because of
delays in obtaining reagents from respective manufacturers.
Results show no change in the adherence and biofilm formation of 29 isolates upon
exposure to NRTIs. In contrast, a steady increase in the number of viable cells was
observed upon exposure to double the peak concentration of lamivudine to 23 of the
clinical isolates. All 31 isolates tested were susceptible to amphotericin B (MIC≤1µg/ml).
Although these results suggest that NRTIs may have little effect on the virulence of C.
albicans it is postulated, that, in a dose-dependent manner, cytidine analogues act similarly
to 5-FU by activating a signal-transduction pathway which stimulates proliferation.
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CHAPTER 1: LITERATURE REVIEW
Fungi, originally classified with plants, are now classified into a fifth kingdom- the
kingdom Fungi, as a result of cell wall differences. They are eukaryotic organisms that
contain chitin in their cell walls. These chemoheterotrophic organisms can be either
unicellular or multicellular. Based on their distinct morphology, fungi are grouped into
yeasts and moulds. An estimated 250,000 species of fungi exist. Of these, only 150 are
known to be pathogenic to humans. Most of these fungi are free-living in nature, with the
exception of Candida, which forms part of the normal flora of humans (Dixon et al.,
1999).
1.1 CANDIDA SPECIES
Candida is a dimorphic commensal yeast that forms part of the endogenous flora of the
mucous membranes of the oral cavity, vagina and gastrointestinal tract of most human
beings (Richardson, 1991; Bernhardt et al. 2001). This opportunistic yeast causes
infections that can either be localized or systemic (Haynes, 2001).
Candidiasis is usually associated with in-dwelling medical devices such as catheters and
heart valves, and in the last few decades, a marked increase in the rate of nosocomial
candidemia has been observed (Meunier et al., 1992; Beck-Sague and Jarvis, 1993; Pfaller
1996; Pfaller et al., 2000).  Candida species have been found to be the fourth leading cause
of nosocomial infections worldwide (Wenzel, 1995). Most of these infections are due to
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Candida albicans, which accounts for 50 - 60% of all nosocomial Candida infections
(Perea and Patterson, 2002). There has, however, been a 46% increase in the rate of
nosocomial infections caused by other Candida species (Fridkin and Jarvis, 1996; Abi-Said
et al.,1997; Levy et al., 1998; Perea and Patterson, 2002; Shin et al., 2002). The most
pathogenic Candida spp. after C. albicans are Candida parapsilosis, Candida glabrata,
Candida tropicalis and Candida krusei, in that order (Kuhn et al., 2002).
Candidiasis is also associated with malnutrition, total parental nutrition, broad-spectrum
antibiotics, immunosuppressive therapy, bone marrow therapy and transplantation,
amongst others (Richardson, 1991; Murray et al.¸1999; Shin et al., 2002; Marais et al.,
2004). In immunocompromised people, e.g. those infected with the human
immunodeficiency virus (HIV), as well as those undergoing cancer treatment,
immunosuppressive therapy, long-term antibiotic treatment or in individuals who are organ
transplant recipients (Richardson, 1991, Anaissie, 1992; Ueta et al., 2001), candidiasis
occurs because immune dysfunction and the suppression of their leukocyte function allows
for auto-infection from endogenous flora (Glick, 1994; Ueta et al., 2001) and infection by
contact with excretions of mouth, skin, and faeces from Candida  carriers (Health Canada,
1999). In healthy humans, cell-mediated immunity has been found to play a significant role
in recovery from oral infection with C. albicans. Data from an experimental murine model
suggests that mucosal-associated immunity may play a protective role against oral
candidiasis, whilst humoral immunity seems to have no part in this protective mechanism
(Farah and Ashman, 2005).  In humans however, it appears that cellular factors play a
protective role mucocutaneous infection, while humoral factors play a larger role in the
prevention of dissemination of Candida infections (Challacombe, 1994).
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The ability of Candida to cause disease is attributed to its virulence factors. These factors
enable this symbiotic yeast to become pathogenic when the host’s defense system becomes
compromised (Murray et al.¸1999; Haynes, 2001).
1.2 CANDIDA VIRULENCE FACTORS
Traits that enable infectious microorganisms to invade and colonise a host are known as
virulence factors (Cole, 2003). In Candida spp. these attributes enable the yeast cells to
establish a niche in the host’s epithelial surfaces where the host’s defense system cannot
efficiently eliminate the infection. This niche also allows the Candida cells to colonise
other tissues, and use the host’s available substrates for growth and reproduction (Cole,
2003). Some virulence factors attributed to Candida spp. are adherence, biofilm formation
and the production of extracellular hydrolytic enzymes.
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1.2.1 Adherence
The first step for colonization, infection and subsequent disease causation by an organism
is its adherence to a host surface. Adherence to host surfaces is also a prerequisite for
subsequent biofilm formation (Cotter and Kavanagh, 2000).
Though little is known about the adherence mechanisms of Candida to oesophageal
epithelial cells, both specific and non-specific interactions are likely to play an important
role in this initial step of oral thrush formation (Cotter and Kavanagh, 2000).
1.2.1.1 Non-specific adherence interactions
Non-specific interactions of electrostatic forces, aggregation and cell surface
hydrophobicity, are the primary mechanisms in the process of adhesion. These occur over
long distances and are reversible (Cotter and Kavanagh, 2000).
Originally, electrodynamic interactions (van der Waals interactions, and hydrophobicity)
were thought to promote adhesion, while the stronger electrostatic ion-ion interactions
were thought not to contribute to the adherence of Candida. In subsequent years, however,
alteration of the electrostatic charge on the surface of C. albicans was shown to affect the
adherence of yeast (Klotz, 1994), and the chemical groups which gave the overall negative
charge of the Candida cell wall were thought to be involved in specific adherence
mechanisms of the organism (Hobden et al., 1995).
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In addition to the electrostatic interactions, hydrophobic interactions of C. albicans with
the epithelium, as with other organisms, are considered to play an important role in the
adherence of this yeast, since the switch from a hydrophilic state to a hydrophobic one
renders the commensal yeast pathogenic (Hazen and Hazen, 1992).  It was also observed
that the hydrophobic Candida cells bound more readily to proteins such as fibrinogen than
hydrophilic yeast cells (Holl, 1992), and it seems that the cell surface hydrophobicity of
Candida contributes to other processes affecting disease progression (Masuoka et al.,
1997).
The overall effect of these non-specific interactions, however, seem less than those exerted
by the specific adherence interactions (Cotter and Kavanagh, 2000).
1.2.1.2 Specific adherence interactions
These interactions, being ligand-receptor interactions, are not reversible. Adherence of
Candida to epithelial cells is quite specific and evidence shows that mannoproteins, and to
a lesser extent phospholipids, sterols and steryl esters, are responsible in mediating this
adherence (Cotter and Kavanagh, 2000).
Both the specific and non-specific adherence interactions exerted by Candida make the
adherence process a complex and multi-component one.
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1.2.2 Biofilm Formation
Biofilms can be defined as structured microbial communities attached to a surface. These
layers of cells, embedded within a matrix of extracellular polymeric material, display
phenotypes distinct from sessile cells, and are responsible for many human infections
(Douglas, 2003).  Biofilm infections can either be caused by bacteria or fungi, as well as
mixed species or mixed genera biofilms. In the environment, mixed species biofilms have
been isolated. These indicate the ability of microorganisms to cohabit within a community
in hostile niches. This co-existence can be parasitic e.g. between C. albicans and
Pseudomonas aeruginosa where P. aeruginosa formed a biofilm on C. albicans filaments,
and killed the fungus, or symbiotic e.g. between C. albicans and Staphylococcus
epidermidis, where increased resistance to chemotherapy was observed (Hogan and Kotler,
2002; Adam et al., 2002).  In the oral cavity, mixed species biofilms with the commensals
Streptococcus salivarius and Streptococcus mitior reduced candidal adhesion while
Streptococcus mutans had no significant effect (Samaranayake and McFarlane, 1982).
Although the role of bacterial biofilms has been extensively studied, very little is known
about fungal biofilms (Ramage et al., 2001; Douglas, 2003).
Candida biofilms have similar properties to bacterial biofilms such as structural
heterogeneity, reduced susceptibility to antimicrobial agents, as well as the presence of
exopolymeric material (Hawser and Douglas, 1995 (a); Baillie and Douglas, 1998 (b);
Baillie and Douglas, 1998). Fungal biofilms, however, are distinct from bacterial ones in
that C. albicans is dimorphic, and as such has the ability to switch from a yeast form to a
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filamentous one. This feature of C. albicans confers unique developmental properties to its
biofilms (Ramage et al., 2001).
1.2.2.1 Development of Candida biofilms
After adherence of the Candida cells to the host epithelium or indwelling device, cell
proliferation and biofilm formation follow during the course of Candida colonization
(Ramage et al., 2001).
Initial adherence of the yeast cells occurs within the first two hours of contact, and during
the next two hours, the cells germinate and form micro-colonies, which are predominantly
budding yeast cells. These budding cells begin to filament, forming pseudohyphae and true
hyphae, after approximately 4-6 hrs. This is followed by the development of a monolayer
(6-8hrs), where neighbouring yeast hyphae merge to form a network of spatially dispersed
filamentous forms. Approximately 8-24 hrs after initial contact, the cells proliferate, and
maturation of the biofilm is observed 24-48 hrs later. This final biofilm matrix is multi-
layered, and is composed of all fungal morphologies (Ramage et al., 2001; Andes et al.,
2004).
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1.2.3 Production of extracellular hydrolytic enzymes
Saprophytic organisms secrete extracellular proteinases, whose primary function is to
breakdown complex materials into nutrients, or to compete with other environmental
organisms (Cunningham and Agard, 2004). Parasitic organisms seem to have modified this
property for use during infection (Naglik et al., 2004). These opportunistic organisms
hydrolyse host cell membrane proteins. This allows for either adhesion and tissue invasion,
or the damage of the host defense system cells, thereby avoiding attack (Klemba and
Goldberg, 2002; Peschel, 2002; Rasmussen and Bjorck, 2002; Rosenthal, 2002; Naglik et
al., 2003).
Candida species have been found to secrete only aspartyl proteinases. Whilst this organism
is in its saprophytic stage, these enzymes are essential for growth when protein is the only
available nitrogen source. However, in its pathogenic state, these Candida enzymes have
been associated with other virulence traits such as adherence, phenotypic switching, and
hyphal formation (Naglik et al., 2003). Secreted aspartyl proteinases, thus, play an
important role in the pathogenicity of Candida (Naglik et al., 2004).
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1.3 ANTIFUNGAL THERAPY
The marked increase in life-threatening fungal infections since the 1980s has been
attributed to several factors, including frequent treatment with broad-spectrum antibiotics
and the increase in the number of immunocompromised individuals (Perea and Patterson,
2002).
As a result of this, pharmaceutical companies have developed antifungal agents with
systemic activities (Espinel-Ingroff, et al. 1999). Today, different classes of antifungal
drugs are available for the treatment of fungal infections (Odds et al. 2003). Figure 1.1
summarizes the mechanisms of action of each class of antifungal described in Section 1.3.1
(Odds et al., 2003).
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1.3.1. Antifungal Agents
The different classes of antifungal drugs have been developed to target different areas of
fungi. Griseofulvin, isolated from Penicillium griseofulvum in 1939, was the first
antimicrobial agent targeted specifically against fungi (Odds et al. 2003). Its use is limited
to the treatment of dermatophyte fungal infections such as ringworm infection and athlete’s
foot (Odds et al., 2003). It is thought to hinder fungal mitosis by interacting with
polymerized microtubules and thus disrupting the fungal mitotic spindle. However, its
exact mechanism of action still remains to be elucidated (Odds et al., 2003).
Agents such as flucytosine, the polyenes and the azoles are discussed at a later stage
(Sections 1.3.1.1, 1.3.1.2 and 1.3.1.3 respectively).
Another class of antifungal agents developed after flucytosine, polyenes and azoles i.e. the
allylamines and phenylmorpholines, act on the ergosterol pathway (Odds et al., 2003). This
class of drugs is used for the treatment of few pathogenic yeasts, as not many are
susceptible to these agents. These drugs are effective only against a small range of fungi,
and have been advocated for the treatment of superficial mycoses (Odds et al., 2003).
The most recent antifungal agents, the echinocandins target proteins responsible for the
synthesis of the fungal cell wall polysaccharides. These have not yet been approved for use
against Candida spp. (Odds et al., 2003), though caspofungin has been approved for use
against invasive aspergillosis (Maertens et al., 2000).
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1.3.1.1 Flucytosine
This compound, also known as 5-fluorocytosine, (Figure 1.2), is an antimetabolite drug.
Figure 1.2: Chemical structure of flucytosine.
This pyrimidine is deaminated within the fungal cell to 5-fluorouracil. The latter in turn
gets incorporated into RNA, causing chain termination and consequently inhibiting protein
synthesis. In addition to this, flucytosine hinders the thymidylate synthetase pathway via 5-
fluorodeoxy-uridine monophosphate, thus effectively inhibiting fungal DNA synthesis
(Figure 1.3) (Kurtz et al., 2005).
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1.3.1.2 Polyenes
This class of antifungal drugs are responsible for fungal membrane alteration (Odds et al.,
2003). The members of this class, nystatin, natamycin and amphotericin B, are all products
of Streptomyces species (Dixon and Walsh, 1996).
Amphotericin B, which was discovered in 1956, remains the mainstay antifungal agent
today due to its broad spectrum of activity against most systemic fungal infections
(Espinel-Ingroff, et al. 1999). It is an amphoteric compound composed of a hydrophilic
polyhydroxyl chain and a lipophilic polyene hydrocarbon chain (Figure 1.4).
Figure 1.4: Chemical structure of amphotericin B
Amphotericin B, unlike other antimicrobials, binds to sterols and not enzymes. Its main
binding site is ergosterol, the primary fungal cell membrane sterol. This interaction
disrupts the osmotic balance of the membrane, leading to leakage of intracellular
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potassium and magnesium ions as well as sugars, metabolites, resulting in cell death. The
exact nature of this fungicidal activity, however, still remains to be elucidated (Odds et al.,
2003).
1.3.1.3 Azoles
The members of this class are composed of five-membered organic rings containing two or
three nitrogen molecules, the imidazoles and triazoles, respectively. Fluconazole and
itraconazole are the most clinically applied azoles (Figure 1.5) (Dixon and Walsh, 1996).
Figure 1.5: Chemical structure of the triazoles A) fluconazole and B) itraconazole
The main mechanism of action of all azoles is the inhibition of cytochrome P450 14-
demethylase, the enzyme responsible for the demethylation of lanosterol to ergosterol in
the erogosterol pathway (Sheehan et al., 1999; Odds et al., 2003). This leads to the
depletion of ergosterol, and replacement with other sterols, thereby resulting in the
alteration of the permeability and fluidity of the fungal membrane (Odds et al., 2003).
A) B)
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The primary target of the azoles is cytochrome P450-Erg11, which catalyses the oxidative
removal of the 14-methyl group of lanosterol by P450 14-demethylase activity. The
P450 protein contains an iron protoporphyrin moiety at its active site, to which the azoles
bind via a nitrogen atom of the imidazole or triazole ring. The other portion of the azole
molecule then binds to the apoprotein according to its individual structure (Odds et al.,
2003).
1.3.2 Antifungal Resistance in Candida spp.
Antifungal resistance is defined as the relative insensitivity of fungi to an antifungal agent
as tested in vitro and compared with other fungi of the same species (Loeffler and Stevens,
2003). Primary resistance, which is observed in organisms never exposed to antifungal
drugs, has been observed in C. krusei with regards to fluconazole. Most other Candida
species, however, develop secondary resistance to antifungal agents (Loeffler and Stevens,
2003).
Secondary resistance of Candida species has been documented mostly with the azoles
(Loeffler and Stevens, 2003). This has been attributed to factors such as alteration of drug
efflux, overexpression of lanosterol demethylase (the azole target), altered sterol (5, 6)
desaturase, and alterations in the plasma membrane composition which affects membrane
fluidity and asymmetry, thus leading to a decrease in the uptake of the drug, (Ghannoum
and Rice, 1999; Loeffler and Stevens, 2003).
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In HIV-positive patients a high prevalence of antifungal drug resistance in Candida species
has been observed (33% fluconazole resistance as opposed to 11% fluconazole resistance
from HIV-negative isolates) (Law et al., 1994).  Johnson and co-workers (1995) attributed
azole resistance mainly to the prolonged fluconazole therapy in the treatment of recurrent
oral candidiasis. Subsequent studies examined the role of Candida virulence traits with
respect to antifungal resistance. Increased adherence, germ tube formation, levels of
secreted aspartyl proteinases and extraphospholipase activity of fluconazole resistant C.
albicans was observed when compared to sensitive isolates in vitro, and the virulence of a
fluconazole-resistant strain proved to be higher than that of a fluconazole-sensitive strain in
vivo (Fekete-Forgács et al., 2000).
Biofilm formation of Candida is also thought to be implicated in antifungal resistance. The
mechanism of action of this increase in resistance of biofilms to antifungals, both in vitro
and in vivo has yet to be elucidated (Hawser and Douglas, 1995; Andes et al. 2004). This
increase in antifungal resistance was previously attributed to low growth rate, matrix
production or unique biofilm-associated patterns of gene expression (Kumamoto, 2002).
Experimental data however suggested that low growth rate was not solely responsible for
antifungal resistance (Baillie and Douglas, 1998). Results from another study by the same
group indicated that production of the biofilm’s exopolymeric matrix also did not
constitute a significant barrier to the diffusion of antifungal agents and the presence of this
extensive matrix did not enhance resistance (Baillie and Douglas, 2000). Though a few
studies have provided clues of the genetic basis for increased antifungal resistance of cells
in a biofilm, this mechanism still remains to be elucidated (Ramage et al., 2002; Lupetti et
al., 2002; Micheli et al., 2002).
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1.4  CANDIDA AND THE AIDS PANDEMIC
The Acquired Immunodeficiency Syndrome (AIDS) pandemic has already caused the
death of over 20 million people globally, and an estimated 39.4 million people are living
with HIV (UNAIDS, 2004). Candida, the main causative agent of fungal infections in
HIV-positive individuals (Jin et al., 2003), causes oral candidiasis which has been
observed in approximately 90% of HIV-infected individuals (Repentigny et al., 2004).
Candidal infections are associated with reduced immune function and lowered numbers of
CD4+ lymphocytes (Patton et al., 1999). Oral candidiasis is one of the first indications of
HIV infection in most individuals (Samaranayake et al., 2002), and it usually presents in
its pseudomembranous form, as smooth white plaques, in the oral cavity of these
individuals (Figure 1.11)
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Figure 1.6: Chronic oral candidiasis of the tongue in an adult with an underlying immune
deficiency showing the characteristic white pseudomembrane
(Courtesy Copyright © The University of Adelaide; Unless expressly stated otherwise, the University of Adelaide claims
copyright ownership of all material on this Internet site. You may download, display, print and reproduce this material in
unaltered form (attaching a copy of this notice) for your personal, non-commercial use. The University of Adelaide
reserves the right to revoke such permission at any time. Apart from this permission and uses permitted under the
Copyright Act 1968 (pdf 1MB), all other rights are reserved. Requests for further authorisations, including authorisations
to use material on this web site for commercial purposes, should be directed to copyright@adelaide.edu.au.).
Candida albicans is the most frequent causative agent of oral candidiasis (Repentigny et
al., 2004). It is part of the oral flora of more than 60% of all human beings (Cassone and
Cauda, 2002), and as such, the most common source of the oral candidiasis is the patient.
Immunocompromised individuals can also be exogenously infected with C. albicans
through nosocomial transmission, sexual transmission and oral transmission (Dromer et
al., 1997; Repentigny et al., 2004).
An increase in the rate of C. albicans carriage as well as an increase in the frequency of
oral candidiasis is usually observed in HIV-positive individuals. It has been suggested that
these increases could be due not only to the compromised immune systems of these
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individuals but may also be attributed to possible alterations in the quality of the host oral
environment and mucosal cells, as well as Candida virulence traits (Jin et al., 2003).
Previous studies comparing adherence (the prerequisite of colonisation), of yeasts from
HIV-positive and HIV-negative patients to mucosal surfaces generated variable data
(Sweet et al., 1995; Pereiro et al. 1997; Tsang et al. 1999). In 2003, Jin and co-workers
proposed that the increase in carriage and frequency of C. albicans in HIV-positive
individuals could be in part due to the enhanced ability of the colonising C. albicans to
produce biofilms on the oral mucosal surfaces. They found no significant differences in the
amount of biofilm produced by isolates obtained from HIV-positive and HIV-negative
individuals. Using a linear statistical model, they found an associated decrease in Candida
biofilm formation in patients younger than 35 years, as well as patients who had CD4+
counts of greater than 350 cells/l, and attributed an increase in biofilm formation to the use
of zidovudine at the time of sampling (Jin et al., 2003).
Tsang et al. (1999) also showed similar results of increased adherence of C. albicans to
buccal epithelial cells in vitro in the presence of zidovudine, which was attributed to
zidovudine-related xerostomia, anaemia, neutropenia, and increase in host cell receptivity
for yeasts. Based on this and their own data, Jin and co-workers suggested that the use of
this antiretroviral nucleoside analogue drug was associated with increased virulence of C.
albicans (Jin et al., 2003).
Historically amphotericin B was the recommended drug of choice for a variety of fungal
infections in HIV/AIDS patients attending state hospitals in South Africa.  However, in the
Literature Review
21
last five years, as part of a Diflucan partnership programme with the South African
Ministry of Health, Pfizer Inc. has made fluconazole available to state hospitals at no cost.
As yet, resistance to fluconazole has not been observed, while an 8.4% resistance to
amphotericin B has been reported (Blignaut et al., 2002(a)).
1.4.1 Antiretroviral Therapy
The implementation of Highly Active Antiretroviral Therapy (HAART) has revolutionised
the treatment of HIV and has considerably improved the quality and length of life of
infected individuals (Field and Laughlin, 1999).
HAART consists of either two nucleoside reverse transcriptase inhibitors and one non-
nucleoside reverse transcriptase inhibitor, or two nucleoside reverse transcriptase inhibitors
and one protease inhibitor. In South Africa two antiretroviral (ARV) regimens have been
instituted in the management of patients on the national “roll out” programme (Table 1)
(Simelela, 2004). The second line regimen is given to patients only when toxicity or
treatment failure occurs with the first line regimen, and regimen 1b is given to women who
can and/or who want to fall pregnant (Simelela, 2004).
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Table 1: The current South African antiretroviral roll out regimens
Line Regimen Prescribed Drugs
1a d4T, 3TC and efavirenz1
st
 line
1b d4T, 3TC and nevirapine
2
nd
 Line 2 AZT, ddI and lopinavir/ritonavir
Key: d4T-stavudine; 3TC-lamivudine; ddI -didanosine; AZT- zidovudine
1.4.1.1 Nucleoside reverse transcriptase inhibitors (NRTIs)
Nucleoside reverse transcriptase (RT) inhibitors are nucleoside analogues that lack a 3’
hydroxyl group required for DNA synthesis. Due to this unique chemical structure, they
inhibit the reverse transcription of viral RNA to DNA by terminating DNA strand
elongation and consequently preventing the completion of the HIV replication cycle
(Weissbrich et al., 2002).  NRTIs also compete for the binding site of the reverse
transcriptase thus competing with the authentic substrate for the catalytic site (Weissbrich
et al., 2002).
The NRTIs currently in clinical use are zidovudine (AZT) and stavudine (d4T), which are
both thymidine analogues; zalcitabine (ddC), and lamivudine (3TC), which are cytidine
analogues and didanosine (ddI), which is an inosine analogue (Gibbon, & Swanepoel,
2000) (Figure 1.7). In these forms, the NRTIs have no anti-HIV activity. Only after
phosphorylation by a host kinase or nucleotidase to their 5’-triphosphate forms do these
drugs exert anti-HIV activities.
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Figure 1.7: Structures of the NRTIs A) ddI, B) 3TC, C) d4T and D) AZT
1.4.1.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Non-nucleoside reverse transcriptase inhibitors are composed of a wide variety of different
chemical classes, and differ structurally from the NRTIs by not being nucleoside or
nucleotide analogues (Weissbrich et al., 2002). Members of this class include nevirapine
and efavirenz (Figure 1.8)
A) B) C)
D)
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Figure 1.8: Structures of the NNRTIs A) nevirapine, and B) efavirenz
NNRTIs which are specific only to HIV-1 reverse transcriptase inhibit reverse
transcription in a non-competitive manner. They are highly selective allosteric inhibitors,
and unlike the NRTIs, do not need to be activated in the cell (Srinivas and Fridland, 1999).
The NNRTIs bind to the unique hydrophobic site of HIV-1-RT, which is distinct from the
catalytic site of the polymerase. This pocket only becomes accessible upon displacement of
the polypeptide chain connecting “palm and thumb” upon the interaction with an NNRTI.
(Huang et al., 1998; Rodgers et al., 1995). This interaction locks the polymerase into an
inactive form by inducing structural changes at the catalytic site. These changes lead to the
alteration of the polymerase shape and thus its function (Weissbrich et al., 2002).
A) B)
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1.4.1.3 Protease inhibitors (PIs)
Protease inhibitors (PIs) are peptidomimetics. There are two types of PIs: type I mimetics
which are synthetic derivatives of short peptides, and type III mimetics which are
chemically unrelated substances (Weissbrich et al., 2002). These drugs bind to the catalytic
site of HIV protease, which is essential for the cleavage of the HIV polyprotein into the
different HIV proteins required for virion assembly. They act as competitive inhibitors
with regards to the natural substrate i.e. viral polyproteins. Most PIs currently in use are
type I mimetics and an example is ritonavir (Figure 1.9) (Srinivas and Fridland, 1999).
Figure 1.9: Structure of the PI ritonavir.
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1.4.2 Effect of HAART on candidiasis
The ability of Candida albicans to cause oral candidiasis in immunocompromised hosts
has been attributed to the decrease in the host’s ability to prevent infection as well as the
organism’s virulence factors (Ramage et al., 2004). Since the introduction of HAART in
1996, a remarkable decrease in oral thrush has been observed in HIV-positive patients
(Ramage et al., 2004). Initially, this was attributed solely to increases in CD4+ cell counts,
decreases in viral load, and immunological reconstitution of host defenses. It was later
observed that HAART resulted only in late and inconsistent recovery of anti-candidal
cellular immunity, and in some patients oral candidiasis was fully treated even before
recovery of CD4+ cell counts and response to Candida antigens (Ramage et al., 2004),
implying that host immune reconstitution was not the only reason for the observed
decrease in oral candidiasis.
Also in 1996, an HIV-positive patient was diagnosed with oral thrush which could not be
treated with fluconazole, itraconazole, amphotericin B or nystatin. Only upon the
introduction of the HIV proteinase inhibitor saquinavir as part of the HAART therapy was
the candidiasis cured (Zingman, 1996). In 1999, the decrease in C. albicans infections in
HIV-positive patients was attributed to the PIs direct inhibition of Candida aspartyl
proteases (Caudel et al. 1999). In addition to the SAP virulence trait of C. albicans, an in
vitro study has also demonstrated that PIs inhibit the adherence of C. albicans to epithelial
cells (Bektic et al., 2001). Whilst inhibition of SAP expression in the oral cavity by PIs and
not NNRTIs were observed (Cassone et al. 1998; Bernardis et al. 1999), results by
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Bernardis et al. did not support the hypothesis that this inhibition could eliminate Candida
or its selection in the oral cavity (Bernardis et al. 1999).
It therefore seems that factors other than PIs and host immunity could affect Candida.
Increases in virulence of the organism may well be triggered by such factors, which can
contribute to HIV-positive individuals eventually developing oral thrush (Sanchez-Vargas
et al., 2005).
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CHAPTER 2: PROJECT
2.1 RATIONALE
The occurrence of Candida in the oral cavities of HIV/AIDS patients usually predicts the
development of oral candidiasis at a later stage, since the anti-Candida activity of oral
epithelial cells is diminished in these immunocompromised individuals (Steele et al., 2000;
Sanchez-Vargas et al., 2005).  Despite the reduction in oral thrush observed since the
introduction of HAART, patients usually develop this infection when their viral loads are
greater than 3000 copies/ml and CD4+ cell counts are less than 200 (Migliorat et al., 2004).
Immune reconstitution inflammatory syndrome (IRIS), a clinical deterioration of the
clinical status of HAART-treated patients despite satisfactory control of viral replication
and improvements in the CD4+ lymphocyte counts, leads to inflammatory responses
towards previously diagnosed or incubating pathogens, as well as unidentified antigens
(Shelburne, 2003). Experimental data showed that IRIS was found to be more pronounced
in patients receiving an NNRTI-HAART regime than those receiving the PI-HAART
regime. This showed that immunological recovery alone upon administration of HAART
did not explain the anti-SAP and anti-oral candidiasis effects of PIs (Cassone, 2002).
In the early 1960s AZT was developed as an anticancer drug, but was never patented as it
proved unsuitable in a clinical setting. It was later shown to be useful against HIV. 5-
fluorouracil, a nucleoside analogue used for cancer treatment was shown to increase
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Candida cell virulence in vitro (Ueta et al., 2001). Since 5-fluorouracil and NRTIs are
structurally similar, we postulate that the NRTIs may have a similar effect on Candida.
In HIV-positive individuals a change in oral Candida flora, (Nguyen et al., 1996, Nho et
al., 1997) and a high prevalence of antifungal resistance, particularly to the triazoles, (Law
et al., 1994; Sanglard and Odds, 2002), has been noted. These make the findings by Jin and
co-workers (2003) and Ueta et al. (2001) of great importance. Virulence changes in
Candida species upon exposure to NRTIs would be of interest in South Africa, since an
estimated 5.5 million South Africans are infected with the virus (UNAIDS, 2006 Report on
the global AIDS epidemic), and oral candidiasis remains the most prevalent fungal
infection (Blignaut et al., 2002). This study could contribute to the design of treatment of
HIV patients with candidiasis.
If an increase in Candida spp. virulence due to NRTIs is observed, this would imply that
patients should be treated for candidiasis with the appropriate antifungal drug prior to
initiation of HAART therapy. It would also re-enforce the need for patients to adhere
strictly to their ARV therapy.
2.2 HYPOTHESIS
Nucleoside analogues used in antiretroviral therapy for HIV/AIDS increase the virulence
of Candida albicans.
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2.3 OBJECTIVES
2.2.1 General Objective
To establish fungal biofilm, proliferation, adherence and antifungal susceptibility assays in
the laboratory, and determine the effects of NRTIs on the virulence of C. albicans.
2.2.2 Specific Objectives
To determine the effects of NRTIs on:
i) Candida biofilm formation
ii) The rate of proliferation of Candida
iii) The adhesion of Candida to epithelial cells
iv) The antifungal susceptibility of Candida to amphotericin B
2.3 ETHICAL CLEARANCE
Establishment of techniques was done using previously identified Candida spp. These
isolates, obtained from Dr M. Patel (Division of Oral Microbiology, Department of
Clinical Microbiology and Infectious Diseases, University of the Witwatersrand), were
collected from HIV-positive individuals. Ethical clearance for such use was obtained from
the Ethics and Biosafety Committee of the University of the Witwatersrand, reference
number M010507.
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Oral swabs were collected from HIV-positive individuals attending the HIV clinic of the
Johannesburg Hospital, just before they started antiretroviral therapy. Patient details were
not known to the investigator, and patient consent was obtained before collection of swabs.
A copy of the consent form is attached as Appendix D. Ethical clearance for use of these
samples was obtained from the Ethics and Biosafety Committee of the University of the
Witwatersrand, reference number M040904.
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CHAPTER 3: MATERIALS AND METHODS
3.1 CHEMICALS, REAGENTS AND MEDIA
All the reagents used in this study were of molecular or analytical grade. A list of all
reagents, and enzymes used as well as the composition of media, buffers, solutions and
stains are found in appendices A, B and C. All primers used were purchased from Inqaba
Biotechnical Industries (Pty) Ltd., South Africa.
3.2 IDENTIFICATION
Identification techniques were validated using Candida albicans (ATCC 90028), Candida
tropicalis (ATCC 750), Candida glabrata (ATCC 90030), Candida krusei (ATCC 6258),
and a clinical isolate of Candida parapsilosis. Patient isolates were subsequently identified
using the same techniques.
3.2.1 Microbiological Identification
Single colonies of each isolate were obtained by streaking each sample onto Sabouraud’s
Dextrose Agar (SDA) containing 0.005% chloramphenicol , and incubated at 36° ± 1°C for
48hrs. This selective medium was chosen for the isolation since it has a high dextrose
concentration and acidic pH, which allows for the selection of fungi (Chapin & Murray,
1999 (b)).
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A loopful of each of the yeast isolates was resuspended in distilled water, and this was
used for further identification.
3.2.1.1 Staining
Staining is one of the most commonly used methods of identifying microorganisms.
3.2.1.1.1 Gram Stain
Gram staining, considered one of the most useful identification tests for microorganisms,
stains yeasts purple (Lauderale et al., 1999; CDC Appendix ML-C) (Figure 3.1). Yeasts
are Gram-positive, though they stain poorly.
One hundred microlitres of each yeast suspension was heat-fixed onto a slide, and the
slides were flooded with crystal violet. After one minute, the stain was rinsed off with tap
water. The slides were then flooded with Gram’s iodine for one minute. After rinsing off
with water, the slides were flooded with Gram’s decolouriser for 10s. These were then
rinsed with water and flooded with safranin counterstain for 30s. The slides were rinsed,
dried and observed with a light microscope at 1000x magnification.
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Figure 3.1: Photograph showing the characteristic phenotypic traits of Candida after a
Gram stain at 1000x magnification
3.2.1.1.2 Periodic Acid Schiff Base (PAS) Stain
This stain is mainly used to detect fungi from clinical specimens. The periodic acid first
hydrolyzes the cell wall aldehydes. The latter then combine with the Schiff base, colouring
the cell wall carbohydrates, yielding the characteristic bright pink-magenta of fungi
(Chapin and Murray, 1999 (a)) (Figure 3.2).
One hundred microlitres of each yeast suspension was heat fixed onto a slide. The slides
were flooded with 0.5% periodic acid for 5mins. After rinsing the slides with tap water, the
slides were completely covered with the Schiff base. These were allowed to stand for
15mins after which the slides were rinsed with running water for 10mins. The slides were
flooded with 1% Light Green Solution (Merck, South Africa), a counterstain, for 1min.
The slides were rinsed with water, air dried and observed at 1000x magnification.
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Figure 3.2: Photograph showing the characteristic phenotypic traits of Candida after a
PAS stain at 1000x magnification
3.2.1.2 Germ Tube Formation
This is one of the defining tests for the preliminary identification of Candida albicans,
since only Candida albicans and Candida dubliniensis form true hyphae (Warren and
Hazen, 1999).
A single colony of each yeast isolate was inoculated in 0.5ml horse serum and incubated at
36°C± 1°C for 2.5 - 3hrs. A drop of each solution was observed under the microscope at
400x magnification for germ tube formation. Candida albicans (ATCC 90028) was used as
the positive control while Candida tropicalis (ATCC 750) was used as the negative control
(Figure 3.3).
A true hypha has no constriction between the blastoconidium and germ tube. C.tropicalis
can develop hyphal initials, but the blastoconidia are larger than those of C.albicans and a
constriction is observed between the blastoconidium and germ tube.
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A)  B)   
Figure 3.3: Photographs showing the presence of a true hypha characteristic of C.albicans
(A) and its absence in C.tropicalis (B)
3.2.2 Molecular Identification
Molecular characterisation is essential for the identification of organisms to the species
level. These tests are quicker and less subjecive than biochemical tests.
3.2.2.1 DNA Extraction
Three methods were evaluated for the extraction of DNA from isolates.
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3.2.2.1a Phenol-Chloroform Extraction
The extraction method is a modification from Robert et al (1995).
A loopful of pure yeast was inoculated in a 50ml centrifuge tube containing 3ml
Sabouraud’s Dextrose broth (SDB). This was incubated at 30°C in a shaker (150rpm)
overnight.
One and a half millilitres of the overnight cell suspension was centrifuged at 900g for
5mins and the supernatant discarded. The pellet was washed with 500l distilled water and
centrifuged at 900g for 5mins, and the supernatant discarded. Five hundred microlitres of
lysis buffer (500l TE buffer + 100l 10% SDS) was then added to the pellet, and
incubated at 65°C for 30mins. Proteins were precipitated by the addition of 100l 5M
potassium acetate and kept on ice at 37°C for 1hr. The cell suspension was centrifuged at
12 000g for 10mins. The supernatant was treated with 100l RNase A (10 mg/ml) at 37°C
for 1hr to degrade any RNA present. Two phenol-chloroform-isoamyl alcohol extractions
were performed, and the tubes were centrifuged each time at 16 000g for 5mins. The
phenol denatured the proteins; the chloroform while also being a protein denaturant
stabilised the boundary formed between the aqueous and phenol phase; and the isoamyl
alcohol prevented the foaming of the mixture during vortexing and helped in the separation
of the organic and aqueous phases. After this procedure, the DNA was present in the
aqueous solution at the top of the tube, leaving the organic matter at the bottom and the
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denatured proteins acting as the separating barrier between both phases.
The DNA was then precipitated with 5M NaCl adjusted to a concentration of 0.1M,
completed with an equal volume of 100% ethanol and placed at –20°C for 1hr. This was
centrifuged at 12 000g for 15mins. The DNA was washed twice with 1ml 70% ethanol and
centrifuged at 20 800g for 3mins. The supernatant was then discarded and pellets were
allowed to air dry. The DNA was resuspended in 100l sterile water, and stored at -20°C
until further use.
3.2.2.1b Quick Extraction Method
A loopful of pure yeast cells was resuspended in 1.5ml sterile water and boiled for 6mins.
This was centrifuged at 20 800g for 4mins. The supernatant containing the DNA was
transferred into a sterile microcentrifuge tube.
3.2.2.1c Roche High Pure PCR Template Preparation Kit Method
A loopful of pure yeast, inoculated in a 50ml centrifuge tube containing 3ml SDB, was
incubated at 30°C in a shaker (150rpm) overnight.
Five hundred microlitres of cells was centrifuged at 3000g for 5mins, and the pellet
resuspended in 185μl phosphate buffered saline (PBS). Ten microlitres of 10mg/ml
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lyticase was then added, and this suspension was incubated for 30mins at 37°C. Binding
buffer (200μl) and proteinase K (40μl) was added to the sample mixture, and was
incubated at 72°C for 10mins. To this, 100μl isopropanol was added and vortexed briefly.
The sample was then pipetted into the upper reservoir of a combined Filter Tube-
Collection assembly, and centrifuged for 1min at 6000g.
The flowthrough and collection tube were discarded, and the filter tube was combined with
a new collection tube. Inhibitor Removal Buffer (500μl) was added to the upper reservoir
and the Filter Tube-Collection assembly was centrifuged at 6000g for 1min.
The flowthrough and collection tube were again discarded, and the filter tube was
combined with a new collection tube. Wash Buffer (500μl) was added to the upper
reservoir of this assembly, and centrifuged at 6000g for 1min. This step was repeated.
This time, only the flowthrough was discarded, and the filter tube was combined with the
same collection tube. This assembly was centrifuged for 10s at 8000g to remove any
residual Wash Buffer.
The collection tube was discarded and the filter tube inserted into a sterile 1.5ml
microcentrifuge tube. Pre-warmed Elution Buffer (200μl at 70°C) was added to the filter
tube and the centrifuged at 6000g for 1min.
The microcentrifuge tube now containing the eluted DNA was either used directly, or was
stored at -20°C for further analysis.
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 3.2.2.2 Multiplex Polymerase Chain Reaction
Multiplex PCR allows for the exponential amplification of DNA with the use of more than
one primer set, thereby permitting more than one DNA target to be amplified in a single
reaction tube.
The reaction was set up as previously described by Li et al., 2003. The reaction is based on
the amplification of the internal transcribed spacer (ITS) regions 1 and 2, which are
sequences of RNA in a primary transcript that lie between precursor ribosomal subunits.
These are removed by splicing when the structural RNA precursor molecule is processed
in a ribosome, and are coded by ribosomal DNA. ITS-1 is located between the 18S gene
and the 5.8S gene, while ITS-2 is located between the 5.8S gene and the 28S gene.
The organisation of the primers’ sequences (Table 2) within the ITS regions, specific for
each organism is shown below, with ITS 4 acting as the universal reverse primer (Figure
3.4).
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 Table 2: Primer sequence and final concentration in multiplex PCR (Li et al., 2003)
Primer Primer Sequence Final Primer
Concentration
CA (Candida albicans) TCAACTTGTCACACCAGATTATT 0.06μM
CP (Candida parapsilosis) GGCGGAGTATAAACTAATGGATAG 0.2μM
CG (Candida glabrata) CACGACTCGACACTTTCTAATT 0.06μM
CK (Candida krusei) GATTTAGTACTACACTGCGTG 0.3μM
CT (Candida tropicalis) AAGAATTTAACGTGGAAACTTA 0.2μM
ITS 4 TCCTCCGCTTATTGATATGC 0.12μM
Figure 3.4: Schematic representation of the organisation of the primer sequences within
the ITS regions
18S rDNA 26S rDNA5.8S rDNA
ITS 4
CT
CPCA
CKCG
ITS 2
ITS 1
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PCR reactions containing 1-10ng of yeast DNA, 12.5μl Roche 2x Master Mix and each
primer at its final concentration (Li et al., 2003)  were made up to a final volume of 25μl
with sterile distilled water. These reactions, all set up in a laminar flow hood using filtered
tips, were performed in the iCycler PCR thermal cycler (Bio-Rad Laboratories Hercules,
CA, USA). The reaction parameters used were according to Chang et al., 2001 (Table 3).
Table 3: PCR reaction parameters (Chang et al., 2001)
Step Temperature Time Number of Cycles
Initial denaturation 94°C 3mins 1
94°C 1min
60°C 1min
Denaturation
Annealing
Extension 72°C 1min
35
Final Extension 72°C 5mins 1
In order to optimize the multiplex PCR reaction for identification of yeast isolates to
species level, C. albicans DNA was used. The reaction yielded PCR product bands when
run on a 2% agarose gel of the expected size (402bp). Increasing the MgCl2 concentration
from 1.5mM to 2mM and 5mM MgCl2 resulted in an increase in the amount of product
visualised (Lanes 3 and 5; Figure 3.5).
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Figure 3.5: Optimization of PCR by titration of the MgCl2 concentrations using C.
albicans DNA. Lane 1: Molecular Marker; Lane 2: PCR Reaction with 1.5mM MgCl2;
Lane 3: Negative control; Lane 4: PCR Reaction with 2mM MgCl2; Lane 5: Negative
control; Lane 6: PCR Reaction with 5mM MgCl2; Lane 7: Negative control
Since the difference in the amount of amplicon produced with reactions containing 2mM
and 5mM MgCl2 was indistinguishable visually (Figure 3.5), 2mM MgCl2 was the
concentration used in later multiplex PCR reactions.
3.2.2.2.1 Detection of PCR Product
Ten microlitres of the PCR product was loaded onto a 1% agarose gel (w/v) made with 1x
TAE buffer and 3.75 x 10
-4 μg/μl ethidium bromide. A commercially available molecular
ladder was used as a marker. The fragments were separated by electrophoresis at 80V in 1x
TAE buffer using a gel electrophoresis system (Amersham Pharmacia Biotech, Uppsala,
Sweden). The separated fragments were then observed (BIORAD Gel Doc 1000 system,
1        2        3        4        5         6        7
402 bp500 bp
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Bio-Rad Laboratories Hercules, CA, USA). The expected PCR product size for each
organism is shown in Table 4.
Table 4: Expected fragment sizes (Li et al., 2003)
Organism Product Size
Candida albicans 402bp
Candida parapsilosis 126bp
Candida glabrata 632bp
Candida krusei 475bp
Candida tropicalis 149bp
PCR products obtained after a multiplex PCR reaction using C.albicans DNA extracted by
all three methods was run on a 2% agarose gel (Figure 3.6) to test the efficacy of each
extraction method.
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Figure 3.6:  Testing the efficacy of three DNA extraction methods tested using C.albicans.
Lane 1: Molecular Marker; Lane 2: DNA extracted using quick boiling; Lane 3: DNA
extracted using phenol-chloroform; Lane 4: DNA extracted using the Roche kit; Lane 5:
Negative control containing no DNA
Although all three extraction methods proved effective in extracting the DNA, as judged
by the presence of the expected 402bp band, visually the quick-boiling DNA yielded the
least amount of product. For subsequent PCR reactions, any of the three methods was used.
The quick-boiling DNA extraction method was the method mostly used as it was quicker,
cheaper, and only small quantities of DNA are required for genetic identification by PCR.
       1              2                 3               4                  5
500 bp
402 bp
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3.3 PREPARATION OF YEASTS FOR THE STUDY OF VIRULENCE TRAITS
After identification, each pure Candida isolate was streaked onto a SDA plate and
incubated overnight at 36°C ± 1°C. A colony was then picked and inoculated into 10ml
SDB supplemented with glucose at a final concentration of 8% to enhance the formation of
biofilm in subsequent assays. This suspension was then incubated at 36°C ± 1°C for 18hrs.
One millilitre of each cell suspension was washed twice in PBS, centrifuged at 3400g for
2mins, and the pellets resuspended in 1ml 0.85% normal saline. The turbidity of each
suspension was adjusted with SDB to the equivalent of 3 x 10
7
CFU/ml, the recommended
cell count (Shin et al., 2002) for determination of biofilm formation. This was achieved by
comparative plate counts and spectrophotometric readings as follows:
Serial dilutions ranging from 10
-1
 to 10
-6
 were prepared for each sample and the
absorbance at 600nm measured using a Jenway Model 6300 spectrophotometer (Jenway,
Division of Barloworld Scientific, Stone, Staffordshire, England). The 10
-2
, 10
-4
 and 10
-6
dilutions for each sample were plated out on SDA plates and incubated overnight at 36°C ±
1°C. The colony forming units per ml were calculated as such:
CFU/ml = (number of colonies x dilution factor)/ volume (ml) spread on plate = Y
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To get to the required 3 x 10
7
CFU/ml cross multiplication was done i.e.
E.g. From calculation 1ml suspension = Y CFU/ml
 Xml suspension = 3 x 107CFU/ml
 X = (3 x 107CFU/ml x 1ml) / Y CFU/ml
The absorbance of each Candida isolate was read at 600nm. As a blank, SDB with 8%
final glucose concentration containing no yeast was used. The yeast concentrations were
then adjusted to 3x10
7
CFU/ml.
3.4 VIRULENCE ASSAYS
3.4.1 Adherence Assay
The assay used was a modification from that described previously by Samaranayake and
McFarlane (1981).
WHCO6 cells (established from biopsy in Prof R. Veale’s Laboratory, Department of
Molecular Cell Biology, University of the Witwatersrand) were cultured in a 3:1 mixture
of DMEM:Ham’s F12 medium (Sigma-Aldrich, South Africa), supplemented with 10%
fetal calf serum (Highveld Biological, South Africa). The cultures were maintained in a
humidified CO2 incubator (Labotech, Forma Scientific, RSA.) at 37° C and 5% CO2. The
day prior to the assay, WHCO6 cells were counted using a haemocytometer, and plated out
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onto 3cm tissue culture dishes (Nalge Nunc International, Denmark) at 10
5 
cells in 2ml per
dish.
On the day of the assay, the cells were washed once with 1ml PBS, and inoculated with
1ml of the prepared yeast cells. These were incubated for 1 hour in a humidified CO2
incubator (Labotec, Forma Scientific, RSA.) at 37° C and 5% CO2, without agitation. The
culture dishes were then washed with 1ml PBS for 30s and fixed with 2ml of 2% formalin
in PBS for 15mins at room temperature under a laminar flow hood. The cells were then
rinsed, air-dried and stained with Gram’s safranin. The number of yeast cells adhering to
100 epithelial cells was counted under a light microscope.
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3.4.2 Biofilm Assay
Production of biofilm, a major virulence factor, was assessed using a method described by
Shin and co-workers (Shin et al., 2002).
PolySorp plates were chosen for this assay as it has a hydrophobic surface that ensures
better binding of lipids. Even though only 1%-7% of the yeast cell wall is lipid-based, this
plate was the most suitable since cell surface hydrophobicity has been shown to play a
major role in the adherence of Candida to host cells (Cotter and Kavanagh, 2000).
Twenty microlitres of each yeast suspension at 3 x 10
7
CFU/ml was inoculated into the
wells of PolySorp plates (Nalge Nunc International, Denmark). One hundred and eighty
microlitres SDB was added into each well, and this was incubated at 36°C ± 1°C for 24h
without agitation. Control wells with no yeast suspensions were also included.
Each well was then washed once with 200l sterile distilled water to remove the non-
adherent cells. Sterile distilled water (200l) was then added to each well and the
absorbance at 405nm was then read using an ELx800 Universal microplate reader
(BIOTEK Instruments, Inc., USA.). Percent transmittance (%T) was being recorded, and it
was obtained as such:
Absorbance = log10(1/T), where T= % Transmittance
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The %T value of each yeast was subtracted from the %T value of the control wells to
obtain the %Tbloc of each well i.e. the amount of light blocked when passing through the
wells. This was done at each time point and for each isolate.
For each yeast isolate, this assay was performed in duplicate for each of the two time
points (24hrs and 72hrs), on two different occasions.
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3.4.3 Proliferation Assay
Proliferation of number of viable cells was determined since this gives an indication of the
number of cells present with the potential to cause candidiasis. The greater this number, the
greater the potential of the organisms to cause disease.
A standard colorimetric assay, the CellTiter 96® AQueous One Solution Cell Proliferation
Assay (Promega), was used as per manufacturer’s instructions. The CellTiter 96® AQueous
One Solution reagent contains a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-2(4-sulfophenyl)2-H-tetrazolium, inner salt; MTS, a
tetrazolium compound and an electron coupling reagent, phenazine ethosulfate, PES. This
solution is bioreduced by the cells into a coloured formazan product by metabolically
active cells. This conversion is made possible by Nicotinamide Adenine Dinucleotide
Phosphate (NADPH) or Nicotinamide Adenine Dinucleotide (NADH) produced by the
dehydrogenase enzymes in the active cells.
Twenty microlitres of the CellTiter 96® AQueous One Solution was pipetted into the wells
of a 96-well microtitre plate. One hundred microlitres of each yeast suspension at 3 x
10
7
CFU/ml was added into the wells. The plate was incubated for 1-4 hours at 36°C ± 1°C.
The absorbance was then recorded using an ELx800 Universal microplate reader (BIOTEK
Instruments, Inc., USA) at 490nm to measure the amount of soluble formazan produced by
cellular reduction of the MTS. Control wells were also included on the plate where only
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SDB was added to the CellTiter 96® AQueous One Solution. This was used to correct any
background absorbance as well as to check for contamination. For each yeast isolate, this
assay was performed in duplicate for each of the two time points (24hrs and 72hrs) on two
different occasions.
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3.5 ANTIFUNGAL SUSCEPTIBILITY TESTING
Antifungal susceptibility of each yeast isolate was performed for amphotericin B (Davies
Diagnostics, South Africa) according to the M27-A method of June 1997 (guidelines of the
Clinical and Laboratory Standards Institute (CLSI) formerly known as the National
Committee for Clinical Laboratory Standards (NCCLS). The minimum inhibitory
concentration (MIC) for each isolate was obtained with the broth microdilution method
using the microtitre plate method.
Amphotericin B was diluted in dimethyl sulphoxide (DMSO) to a concentration of
3200g/ml. This was serially diluted (1/10) to a final concentration of 0.03g/ml. A 100l
volume of each dilution was inoculated in wells 1-11 of a flat bottom microtitre plate. To
each of these dilutions, 100l of 0.5-2.5 x 103 CFU/ml of each yeast isolate was added. A
positive control i.e. “yeast with no amphotericin B” was added into well 11 of the
microtitre plate, and a negative control i.e. “RPMI with no yeast” was added into well 12.
The plates were then incubated at 36°C ± 1°C for 48hrs, and evaluated visually, by eye,
observing the presence or absence of visible growth. The MIC was defined as the lowest
concentration of amphotericin B that prevented all visible growth, when compared to
positive controls. As a technical control, C.albicans ATCC 90028 was used.
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3.6 EXPOSURE OF CANDIDA ALBICANS TO NUCLEOSIDE REVERSE
TRANSCRIPTASE INHIBITORS
3.6.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
The NRTIs currently recommended for use in South Africa (Simelela, 2004) are
didanosine (ddI), lamivudine (3TC), stavudine (d4T) and zidovudine (AZT). The ARVs
used in this project were kindly donated by Ranbaxy Laboratories Ltd. (Pharma
Manufacturing, Dewas, India).
3.6.2 Collection and Sample Identification of Patient Isolates
Oral swabs were collected from antiretroviral-naïve patients attending the HIV clinic of the
Johannesburg Hospital, South Africa, prior to initiation of antiretroviral therapy. Patient
attendance at this clinic is by referral, and patients attending this clinic are World Health
Organisation (WHO) Stage IV HIV/AIDS individuals, or have CD4+ counts
<200cells/mm
3
.
Forty-five oral samples collected using sterile cotton swabs from the tongue and/or palate
of patients, were plated out on SDA containing 0.005% chloramphenicol within 3hrs of
collection, and incubated at 36°C ± 1°C for 48 hours. All yeast isolates were identified
using the microbiological and molecular identification techniques described in Section 3.2.
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3.6.3 Virulence Assays and Antifungal Susceptibility Testing
All isolates were prepared as described in Section 3.3.
Prior to virulence and antifungal susceptibility assays, all isolates were exposed to the
anticipated in vivo peak concentration (Goodman & Gilman’s, 2001), double the peak
concentration and half the peak concentration of each NRTI in Sabouraud’s Dextrose broth
for 24 and 72hrs (Table 5).
Table 5: Concentrations of NRTIs used
Concentration/ARV ddI 3TC Stavudine AZT
_ Peak Concentration 1.05μg/ml 0.5μg/ml 0.6μg/ml 0.8μg/ml
Peak Concentration 2.1μg/ml 1.0μg/ml 1.2μg/ml 1.6μg/ml
2x Peak Concentration 4.2μg/ml 2.0μg/ml 2.4μg/ml 3.2μg/ml
In the case of the biofilm assay, all NRTIs (at the abovementioned concentrations) were
added to the yeast cells before inoculation in PolySorp microtitre plates (Nalge Nunc
International). Unless otherwise stated, adherence, biofilm, proliferation and antifungal
susceptibility assays were performed as described in Sections 3.4.1, 3.4.2, 3.4.3 and 3.5
respectively. In all assays Candida isolates grown in the absence of NRTIs were used as
controls.
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3.7 STATISCAL ANALYSES
3.7.1 Determination of Sample Size
In consultation with a biostatistician, Dr P. Becker  (Biostatistics Unit, Medical Research
Council, Pretoria, South Africa), a minimum sample size of 20 patients was decided upon
as there would be adequate degrees of freedom for testing the hypotheses of interest using
the appropriate analysis of variance (ANOVA).
3.7.2 Analyses of the Results
An analysis of variance was performed using the software Statistix 8.0. A cross-sectional
time-series regression model with random effects was employed.
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CHAPTER 4: RESULTS
4.1 IDENTIFICATION
Techniques were established and validated using the control yeasts Candida albicans
(ATCC 90028), Candida glabrata (ATCC 90030), Candida krusei (ATCC 6258), and a
clinical isolate of Candida parapsilosis (Figure 4.1) as described in Chapter 3,  Section 3.2.
A)     B)     
C)   D)  E) 
Figure 4.1: SDA plate showing the characteristic colonial morphologies of C. albicans
(A), C. parapsilosis (B), C. glabrata (C), C. krusei (D), and. C. tropicalis (E).
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Gram-stains and PAS stains revealed the characteristic phenotypes of yeast (Figures
3.1&3.2).
Multiplex PCR reactions set up to confirm the species of each control strain showed the
expected band size for each control strain (Table 4) (Figure 4.2).
Figure 4.2: A 2% agarose gel showing products of a multiplex PCR of each control yeast;
Lane 1: Molecular Marker; Lane 2: C. albicans - 402bp, Lane 3: C. parapsilosis - 126bp,
Lane 4: C. glabrata- 632bp, Lane 5: C. krusei - 475bp, Lane 6: C. tropicalis - 149bp, Lane
7: No DNA control.
500bp
700bp
  1        2       3       4        5       6      7
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Of the forty-five oral swabs collected from HIV-positive patients attending the
antiretroviral (ARV) clinic of the Johannesburg Hospital, South Africa, prior to initiation
of antiretroviral therapy, thirty nine of the isolates were identified as C. albicans, while six
of the isolates remained unidentified. It is possible that these were either C. albicans
isolates that did not have the IS1 genotype (Blignaut et al. 2002(b)), or Candida dubliniesis
since the isolates produced true hyphae but were not identified C. albicans using the
multiplex PCR. Since C. dubliniensis primers were not used in the multiplex PCR reaction,
this was not conclusively proven.
4.2 PREPARATION OF YEASTS FOR THE STUDY OF VIRULENCE TRAITS
The absorbance of each control broth (Table 6) was read at 600nm.
Table 6: Absorbance of each control strain at 600nm
Control Strain Absorbance at 600nm
Candida albicans (ATCC 90028) 1.370
Candida parapsilosis (JHB Hospital outbreak) 0.741
Candida glabrata (ATCC 90030) 1.113
Candida krusei (ATCC 6258) 0.868
The number of colonies produced after plating 10
-2
, 10
-4
, and 10
-6
 serial dilutions of each
yeast onto SDA were counted (Table 7).
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Table 7: Number of colonies obtained with each serial dilution
Number of colonies
Control Strain 10
-2
 dilution 10
-4
 dilution 10
-6
 dilution
C. albicans (ATCC 90028) Too many to count 12 0
C. parapsilosis  (JHB Hospital outbreak) Too many to count 11 0
C. glabrata (ATCC 90030) Too many to count 19 0
C. krusei (ATCC 6258) Too many to count 12 0
Using the 10
-4
 dilutions, the colony forming unit per ml (CFU/ml) for each yeast was
obtained (Table 8).
Table 8: CFU/ml of each control strain
Control Strain CFU/ml
C. albicans (ATCC 90028) 1.2 x 10
8
C. parapsilosis (JHB Hospital outbreak) 1.1 x 10
8
C. glabrata (ATCC 90030) 1.9 x 10
8
C. krusei (ATCC 6258) 1.2 x 10
8
For subsequent assays, each cell suspension was adjusted to 3 x 10
7
 CFU/ml. This was
achieved using the values in Table 8 as described in Section 3.3.
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After a 3 x 10
7
CFU/ml cell suspension of each patient isolate was obtained, the cells were
grown in the anticipated in vivo peak concentration, double the peak concentration and half
the peak concentration of ddI, 3TC, stavudine and AZT for 24 and 72 hours, in duplicate
and on two different occasions.
After each time period, the virulence traits of biofilm formation, proliferation, and
adherence to epithelial cells were tested, to assess the effects of each NRTI.
4.3 VIRULENCE FACTORS ASSAYS
The assays were validated using control yeasts. Comparisons of growth at different
concentrations of NRTIs and for different time intervals were with respect to growth in the
absence of NRTIs, which was used as the baseline.
The results obtained for all assays performed in the presence of NRTIs are tabulated in
Appendix F. The summary of the total effects of each NRTI at each concentration are
represented as figures.
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4.3.1 Adherence Assay
This assay was only performed on clinical strains as described in Section 3.4.1. The
number of adherent yeast cells to 100 fixed oesophageal cells was counted microscopically
for 29 of the 39 C. albicans isolates (Figure 4.3) due to delays in obtaining reagents from
the respective manufacturers.
Figure 4.3: Example of two yeast cells adhering to an epithelial cell at 400x magnification.
The effect of each NRTI on the adherence of the yeast is represented diagrammatically
below (Figure 4.4). The values of the isolates exposed at each time point was compared to
the value of the controls at that time point. At all three concentrations of ddI, 3TC, d4T and
AZT, the mean number of yeast cells adhering to 100 epithelial cells did not differ
significantly from that grown in NRTI-free medium (p>0.05).
Results
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4.3.2 Biofilm Assay
This assay was performed as described in Section 3.4.2.
To establish this assay, control yeasts were used. The %Tbloc for each yeast was
reproducible on both occasions, as shown by the error bars which represented standard
errors of the means (Figure 4.5). The amount of biofilm formed differed between Candida
species. C. albicans produced the least amount of biofilm, followed by C. krusei, and C.
glabrata, while C. parapsilosis produced the greatest amount of biofilm.
Figure 4.5: Biofilm formation of control strains as assessed by calculating %Tbloc using the
absorbances obtained for each stain at 405nm. Error bars represent the standard error of the
means.
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The extent of biofilm formation was then measured spectrophotometrically for only 29 of
the 39 clinical isolates (Figure 4.6) due to delays in obtaining reagents from the respective
manufacturers. All values obtained were differences from zero i.e. the baseline, since the
%Tbloc calculation took into account the yeasts grown in the absence of NRTIs. This
calculation gives an indication of the amount of biofilm formed upon treatment with
NRTIs, such that only the net effect of exposure to the drug would be determined. The “No
ARV” baseline was obtained separately for each isolate exposed to each NRTI at each time
points. Hence, negative values indicate that the isolates produced less biofilm when
exposed to NRTIs, while positive values indicate that isolates produced more biofilm upon
exposure to NRTIs than the control.
The results (Figure 4.6) showed no significant difference in the extent of biofilm formation
of the yeasts upon exposure to each NRTI concentration (p>0.05). This large variation
observed (error bars) could be as a result of the fact that the analysis took into account all
C. albicans isolates. However, each patient isolate may have produced different amounts
of biofilm. As a result, it was concluded that the ARVs had no effect on this virulence
factor.
Results
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4.3.3 Proliferation Assay
This assay was performed as described in Section 3.4.3.
To establish this assay, the coloured formazan product formed by metabolically active cells
was detected for each control yeast strain. C. parapsilosis produced more viable cells than
C. krusei, which in turn had more viable cells than C. glabrata. C. albicans was the control
yeast that produced the least number of viable cells. This assay, performed in duplicate on
six different occasions, was reproducible as observed by the small error bars (Figure 4.7).
Figure 4.7: Number of viable control yeast cells as assessed spectrophotometrically at
490nm using a colorimetric assay. Error bars represent the standard error of the means
(SEM).
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This colorimetric assay was then used to determine the number of viable cells of 23
clinical isolates when exposed to NRTIs (Figure 4.8). Of the 39 C. albicans isolates, 23
were used in this assay due to delays in obtaining reagents from the respective
manufacturers.
At all three concentrations of the NRTIs ddI, d4T and AZT, the rate of proliferation of C.
albicans did not differ significantly from that yeast grown in medium devoid of ARV
(Figure 4.8 A, C, D). A significant increase in the rate of proliferation was however
observed when C. albicans isolates were grown in double the peak concentration of 3TC
recommended for an adult HIV-positive individual (p<0.001) (Figure 4.8 B), at both time
points.
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4.5 ANTIFUNGAL SUSCEPTIBILITY ASSAY
C. albicans ATCC 90028 was used to establish the antifungal susceptibility assay in the
laboratory. This test performed in duplicate on two separate occasions yielded an MIC of
1g/ml of amphotericin B. This value indicates that the yeast was susceptible to
amphotericin B. The MIC guidelines established by the CLSI indicate that MIC range of
sensitive Candida to amphotericin B is 0.5-1μg/ml.
Thirty-one isolates were chosen for this assay because those were the isolates used in the
virulence assays. The MICs obtained for these patient isolates were the same for each of
two occasions tested. Growth of isolates in media containing each NRTI at all three
concentrations for 24hrs and 72hrs yielded identical MICs of 1g/ml of amphotericin B,
when compared to the yeasts grown in media devoid of ARVs. Thus, in our clinical
isolates, NRTIs had no effect on the susceptibility of C. albicans to amphotericin B.
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CHAPTER 5: DISCUSSION
The opportunistic organism Candida albicans is known to cause both localised and
systemic infections in humans (Haynes, 2001). Globally, C. albicans remains the principal
causative agent of oral thrush (Spencer, 2005). The worldwide trend shows that
approximately 90% of all HIV-positive individuals develop oral candidiasis at least once
during the course of their disease, progression from HIV-positive to full blown AIDS
(Repitigny et al., 2004). A large study performed using Candida isolates obtained from the
oral cavities of 339 HIV-positive individuals attending three comprehensive care AIDS
clinics in Pretoria and GaRankuwa, Gauteng Province, South Africa showed that
approximately 90% of these isolates were identified as C. albicans (Blignaut et al., 2002).
These results were similar to those obtained in Thailand where C. albicans was the most
recovered Candida sp. in HIV-positive individuals (96.67%) (Teanpaisan & Nittayananta,
1998). Another study performed in South Africa found the overall Candida carrier rate
(81.3%) in HIV-positive individuals in South Africa to be higher than in Italy (61.9%) and
Thailand (66.67%) (Campisi et al., 2002; Teanpaisan & Nittayananta, 1998). The C.
albicans carriage was however lower at 78.6% in South Africa when compared to 96.67%
in Thailand (Patel et al., 2003; Teanpaisan & Nittayananta, 1998).
To answer the question of whether HIV nucleoside analogue drugs have a similar effect as
5-FU on the virulence of Candida albicans, we collected Candida isolates from the oral
cavities of ARV-naïve HIV-positive individuals attending the HIV Clinic of the
Johannesburg Hospital, Gauteng Province, South Africa. Identification of these isolates
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showed that out of 45 Candida isolates collected, 39 were C. albicans (87%), while 6
isolates (13%) were considered to be either C. albicans isolates that did not have the IS1
genotype (Blignaut et al. 2002(b)) or C. dubliniensis by a process of elimination. Although
the sample size is small, these results are similar to Patel and co-workers’ (2003) where out
of 173 isolates obtained from HIV-positive individuals attending two ARV clinics in the
same province, 78.6% were identified as C. albicans, and whilst 6.3% were C.
dubliniensis.
It is generally accepted that various molecules may have an effect on the virulence of
pathogenic organisms. Some of these molecules increase the virulence of these organisms,
whilst others, such as non-steroidal anti-inflammatory drugs decrease their pathogenicity
(Alem and Douglas, 2004). This is no exception with C. albicans. In 2001, Ueta and
colleagues demonstrated that 5-fluorouracil, a cancer nucleoside analogue, increased the
virulence of two C. albicans isolates in vitro. To assess the effects of HIV/AIDS
nucleoside analogue drugs on the virulence of the C. albicans, isolates collected were
grown in media containing didanosine (ddI), lamivudine (3TC), stavudine (d4T) and
zidovudine (AZT). Biofilm, adherence and proliferation assays were then performed to
determine the effects of these drugs on the virulence factors adherence, biofilm formation
and proliferation. In addition, an antifungal susceptibility assay was also used to determine
what effect the above drugs would have on the susceptibility of these yeasts to an
antifungal agent. All isolates were assumed to be genetically different since they were
obtained from different patients. Due to cost and time limitations, fingerprinting was not
performed to confirm this.
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Adherence Assay
Adhesion of microorganisms to host cells is the first step of pathogenesis (Sundstrom,
2002).
To determine the effect of HIV nucleoside analogues on the adherence of C. albicans to
epithelial cells, 29 isolates grown in the presence of each NRTI were allowed to adhere to
oesophageal cells in vitro. The mean number of adherent yeasts to 100 oesophageal cells
was comparable for the isolates grown in NRTI-free media and those grown in the
presence of NRTIs at all three concentrations (half the peak, the peak and double the peak
concentrations recommended for an AIDS patient) (p>0.05). Previous experimental data
has attributed increased adhesion of C. albicans to epithelial cells to a 4-fold increase in
the binding activity of concanavalin A (a mannose residue) (Ueta et al., 2001). It is
possible that in this case, the NRTIs did not promote the expression of molecules that bind
to mannose residues or other molecules involved in adherence. Since the epithelial cells
used in this study were obtained from a biopsy, cells should express adherence receptors
similar to the in vivo situation. However, immortalisation of the cell line and passaging
may have had an effect on this expression. The most likely explanation for the results
obtained in this study is that the NRTIs had no effect on mechanisms that trigger the
virulence trait of adherence in the system used.
Contradictory data have been reported with regard to differences in adherence properties of
Candida isolates, from both HIV-positive and HIV-negative individuals, to buccal
epithelial cells (BECs). Enhanced adherence of HIV-positive C. albicans to BECs (Sweet
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et al., 1995), less adherence of C. albicans from patients in the initial AIDS stages to BECs
Pereiro et al., 1997), as well as similar adherence of C. albicans from HIV-positive and
HIV-negative to BECs (Tsang et al., 1999) have been reported. In HIV-positive
individuals an increase in the rate of C. albicans carriage and frequency of oral candidiasis
has also been observed (Jin et al., 2003). Jin and co-workers (2003) suggested that this was
as a result of the compromised immune systems and, possible alterations in the oral
environment and mucosal cells. It seems that the quality and quantity of saliva in HIV-
positive individuals during the course of their disease affects adherence and colonization of
the yeast to the BECs. Saliva is made up of components such as lysozyme and histatins
which have anti-candidal properties (Samaranayake et al., 2002). HIV infection has been
noted to have an effect on these components (Samaranayake et al. 2002). It seems that
factors such as the inability of some of these proteins to interact with C.albicans may play
a role in the reduced anti-candidal effect of saliva in HIV-positive individuals (Repitigny et
al., 2004). In this study, adhesion was assessed in the absence of the normal oral
environment (i.e. no saliva), and it is likely that alterations in the oral environment of
immunocompromised individuals plays a significant role in the increased carriage and oral
thrush observed which was not seen in the in vitro system. It would be interesting to
conduct the adherence experiments in an environment similar to that of the oral cavity in
order to assess whether or not NRTIs affect components such as histatins to increase their
antifungal activity.
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Biofilm Assay
Biofilms are responsible for a large number of infections that afflict humans (Douglas,
2003). The ability of Candida to produce biofilms is believed to be an important virulence
trait. These Candida biofilms show increased resistance to antifungal therapy and the cells
within the polymeric matrix can resist the host’s immune system (Shin et al., 2002).
In this study the average amount of biofilm produced by each control Candida strain was
in keeping with observations made by previous workers, in that C. parapsilosis formed the
most biofilm followed by C. glabrata and then by C.albicans in SDB medium containing
8% glucose (Shin et al., 2001).  Based on these observations, and the small standard
deviations obtained for repeat experiments, it was concluded that the experimental system
was adequate and could be used for clinical isolates. The results also showed that C.
albicans produced biofilm in the presence of glucose-rich media, as seen previously (Jin et
al., 2003).
To determine the effect of the HIV nucleoside analogues on biofilm formation, 29 C.
albicans isolates were grown in the presence of the NRTIs at various concentrations. When
the amount of biofilm produced was compared to that produced when the isolates were
grown in media devoid of the NRTIs, no observable significant difference was noted
(p>0.05). The difference between the two time points was still not statistically different, as
C. albicans grown for longer periods of time, i.e. 72hrs as opposed to 24hrs, did not make
any difference in the amount of biofilm produced (p>0.05).
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These results differ from others (Tsang et al., 1999; Jin et al., 2003), where statistical
models correlated increases in biofilm formation with exposure to AZT. The difference
could be attributed to the fact that another in vitro system was used. However, because
regression studies linked a higher degree of biofilm formation of C. albicans with exposure
to AZT (Jin et al., 2003), it would be interesting to study the effect of each NRTI on the
biofilm producing ability of C. albicans in an in vitro environment that more closely
mimics the in vivo situation. It may also be interesting to study the effect of NRTIs on C.
albicans quorum sensing in a more physiological biofilm model.
Proliferation Assay
The ability of an organism to proliferate is of importance to the disease process. The
greater the number of cells produced, the higher the chance the organism may cause
disease (in the presence of other virulence factors). In immunocompromised individuals,
Candida cells proliferate easily because, amongst others, the Candida-killing activity of
phagocytes is suppressed (Ueta et al., 2001).
Experiments with Candida control strains showed that the assay was able to detect
proliferation over time, with little variation seen between replicates and repeat
experiments.
Previous experimental data have revealed increases in C. albicans proliferation upon
exposure to 5-FU (Ueta et al., 2001). The authors suggested that it was likely that the
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multiplying cells were less sensitive to 5-FU, with the more sensitive ones being killed by
the drug.  Upon treatment of C. albicans with ddI, d4T, and AZT, no significant difference
in the number of proliferating viable cells was observed when compared to the yeasts
grown in the absence of these drugs (p>0.05). However, when the isolates were grown in
double the anticipated peak concentration of 3TC in an adult HIV/AIDS patient, at both
24hrs and 72hrs, an increase in the number of viable cells was noticed (p<0.001). The
observations made by Ueta and co-workers (2001) indicated that 5-FU either potentiates
the virulence of Candida cells or they eliminate the cells of low virulence thereby
increasing the risk of oral and systemic candidiasis. In contrast, results in this study seem
to suggest that only potentiation of Candida cell virulence is responsible for increases in
proliferation since 3TC has no anti-fungal activity per se, as it as a nucleoside reverse
transcriptase inhibitor.
3TC differs from the other NRTIs used in this study in that it is a cytidine analogue. This
agent seems to act similarly to 5-FU which also increases proliferation of C. albicans in a
dose-dependent manner (Ueta et al., 2001).  The mechanism of action by which 5-FU
prevents DNA strand elongation is comparable to that of other anti-cancer cytidine
nucleoside analogue drugs, where the phosphorylated drugs get incorporated into the DNA
and subsequently prevent DNA strand elongation (Damaraju et al., 2003).  Since the main
difference between the two kinases responsible for this (thymidine kinase for 5-FU and
cytidine kinase for 3TC) is the presence of a 2’–OH group on the pentose of the cytidine
residue which is absent on pentose of the thymine residue, it is suggested that anti-cancer
cytidine nucleoside analogue drugs increase the virulence of Candida cells in a similar
manner to 5-FU.
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5-FU has been reported to stimulate the proliferation of eukaryotic cells by activating a
signal-transduction pathway (Wu et al, 1998). Vital processes such as DNA replication and
mitosis are triggered by a cell-cycle control system. This system is made up of two phases
(S and M) and two checkpoints (G1 and G2). In the G1 phase the cells grow to an
appropriate size where they are large enough to enter the cell cycle. At this checkpoint the
cell checks whether the environment is favourable for cell proliferation. If it is, the cell
proceeds to the S phase. Otherwise, the cells go into a stationary phase known as START
or G0 (Alberts et al., 1998).
In the S-phase, the DNA replication machinery is set into motion, and the DNA is
replicated. After this, the cell proceeds to the G2 checkpoint where the cell ensures that
DNA replication is complete. If this is complete, the cells proceed into the M phase where
the cell undergoes mitosis. The G1 and G2 checkpoints allow the cell system to be
regulated by signals from other cells, e.g. growth factors, as well as other extracellular
signal molecules which promote or inhibit cell proliferation (Alberts et al., 1998).
Extracellular signals that stimulate cell proliferation lead to the activation of G1 cyclin-
dependent protein kinases complexes. These then phosphorylate the Retinoblastoma (Rb)
protein, thus changing its conformation. This change results in the release of bound gene
regulatory proteins which then activate the genes responsible for cell proliferation. These
extracellular signals override the signals that stop cell proliferation (Alberts et al., 1998).
Wu and colleagues (1998) have demonstrated that addition of 5-FU to 5-FU-resistant
human cells results in an increase in the amount of mitogen-activating protein (MAP)
kinases produced. Filamentation and C .albicans virulence are regulated by two-parallel
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signalling cascades, one of which is through the MAP-kinase pathway (Lengler et al.,
2000). Given that 3TC is a cytidine analogue, it is not implausible that this drug may act in
a similar manner to 5-FU, and activates the MAP-kinase signalling pathway, thereby acting
as an extracellular signal stimulating cell proliferation. Because cytidine has been found to
induce the production of uridine phosphorylase and thymidine phosphorylase, two key
enzymes in DNA replication (Vita et al., 1983), it is also possible that 3TC induces
production of these enzymes, which leads to more DNA replication.
On the other hand, because resistance of eukaryotic cells to 5-FU has mainly been
attributed to over-expression of thymidylate synthase (Marsh, 2005), this over-expression
might also be responsible for the increases in the amount of MAP-kinases produced when
5-FU is added to resistant cells. As such, if 3TC induces over-expression of thymidylate
synthase, the MAP-signaling pathway may be upregulated, and therefore increase
proliferation.
Antifungal Susceptibility
Since the 1980s an increasing trend of fungal infections has been observed. This has been
attributed to the increase in the number of immunosuppressed individuals, especially those
infected with HIV (Espinel-Ingroff et al., 1999). As a result of this, a wide variety of
antifungal drugs have been developed to combat these infections by targeting various
components of the fungal cell. Amphotericin B is an established antifungal agent, with
broad spectrum activity, that binds to ergosterol resulting in membrane damage. It is used
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for the treatment of invasive fungal infections when conventional therapy (with azoles) has
failed (Espinel-Ingroff et al., 1999).
A study carried out in Venezuela showed that most Candida albicans isolates obtained
from HIV-positive individuals (66 out of 67) were susceptible to amphotericin B (Magaldi
et al., 2000). The situation in South Africa, another developing country, appears to be
different. Susceptibility testing of 446 C.albicans isolates obtained from HIV-positive and
HIV-negative individuals showed an 8.4% overall resistance to the drug (Blignaut et al.,
2002). The susceptibility profiles of the two groups (HIV-positive and HIV-negative) were
similar. In this study, all 31 isolates of C. albicans grown in all NRTI concentrations, and
subjected to different concentrations of amphotericin B, were susceptible to the drug (MIC
<1μg/ml). No effect of NRTIs on the susceptibility of C. albicans to amphotericin B has
been observed in our study. However our sample size was small and no conclusions can be
drawn with this finding.
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CHAPTER 6: CONCLUSION
This study addressed the research question of whether HIV nucleoside analogue drugs
increase selected virulence traits of Candida albicans. Of the three virulence traits of C.
albicans studied, only the rate of proliferation was increased upon exposure to 3TC. It may
be that 3TC acted in a similar manner to 5-FU by increasing the rate of proliferation of C.
albicans in a dose-dependent manner and potentially enhancing the virulence of C.
albicans.
It would be worthwhile performing similar experiments with ddC, another HIV cytidine
analogue drug, to see if this too acts in a similar manner to 3TC.  If this occurs, signalling
pathway-studies would be required to determine the mechanism of action of HIV cytidine
analogue drugs on the rate of proliferation of these yeasts. However, since proliferation
was the only virulence trait to be significantly affected by one of the four NRTIs used, this
data suggests that NRTIs may have little effect on the virulence of C. albicans.
Although in vitro simulations form the basis for subsequent in vivo studies, the findings of
this study cannot be extrapolated to predict the effect of NRTIs on C. albicans in a clinical
setting since there are significant differences between in vitro models and human disease.
Nonetheless, in vitro testing of NRTI effects on C. albicans infection may adequately
model some aspects of the drugs on human candidal disease, and give insight to underlying
mechanisms. With the increasing number of immunocompromised individuals globally,
the development of new cytidine analogue drugs against HIV or cancer would necessitate
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the testing of their effects on opportunistic yeasts such as Candida. The effects of these
drugs on virulence traits such as enolase activity and secreted aspartyl protease activities
should also be studied in addition to the characteristics examined here. Increases in the
proliferation of Candida or other yeasts as a result of application of these drugs, may result
in a greater risk of oral disease. This could mean persistent localized and even systemic
disease, which in turn would decrease the quality of life of these individuals.
Future clinical studies may be warranted to specifically evaluate whether NRTIs and/or
other cytidine analogue drugs affect the Candida infection outcome in HIV patients on
ARV therapy using an in vivo model.
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CHAPTER 8: APPENDICES
Appendix A: Table of Chemicals used and their Suppliers
All chemicals and reagents used in this study were of analytical or molecular quality.
Chemicals and Reagents Source
Agarose
Amphotericin B
Whitehead Scientific-Brakenfell, South
Africa
Davies Diagnostics, South Africa
Boric acid
Bovine serum albumin
Sigma-Aldrich
Amersham Biosciences- Uppsala, Sweden
Crystal violet NHLS Diagnostic Media Products, South Africa
DNA 100bp molecular weight marker
DMEM
Promega
Sigma-Aldrich
EDTA
Ethanol (99.7-100%)
Sigma-Aldrich
Analar- Midrand, South Africa
Fetal calf serum Highveld Biological
Glacial acetic acid
D-Glucose monohydrate
Gram decolourizer
Merck
Merck
NHLS Diagnostic Media Products, South Africa
Ham’s F12 medium
Hydrochloric acid
Horse Serum
Sigma-Aldrich
Merck
South African Vaccine Producers (Pty) Ltd
Isoamyl alcohol
Isopropyl alcohol
Iodine
Sigma-Aldrich
Sigma-Aldrich
NHLS Diagnostic Media Products South Africa
6x Blue/Orange Loading Dye G190A
Light Green Solution
Promega
Merk
Magnesium chloride
Mineral oil
Roche Applied Science
Sigma-Aldrich
O’ Gene Ruler DNA Mix #SM1178
O’ Gene 1kb DNA Ladder #SM1168
Fermentas
Fermentas
PCR grade water
PCR Master Mix
Phenol-chloroform-isoamyl alcohol
Potassium acetate
Periodic Acid
Pulsed field gel electrophoresis agarose
Pulsed field gel electrophoresis marker I
Roche Applied Science
Roche Applied Science
Sigma-Aldrich
Analar- Midrand, South Africa
Saarchem, Merk
Bio-Rad Laboratories- Hercules, CA,USA
Bio-Rad Laboratories
Safranin
Schiff Base
Sodium chloride
Sodium dodecyl sulphate (SDS)
Sodium hydroxide
NHLS Diagnostic Media Products, South Africa
BDH, VWR International Ltd, Poole, England
Merck
Merck
Merck
Tris Roche Applied Science
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Appendix B: Media, Buffers and Stains
All solutions and media were obtained from the Diagnostics Media Products Division of the
National Health Laboratory Services (NHLS), Sandringham, South Africa.
1. 2% Agarose (40ml)
0.4g Agarose
40ml 1x TAE buffer
1.5μl Ethidium bromide (10μg/ml)
Media
1. Sabouraud’s Dextrose Agar with Chloramphenicol
10g Mycological Peptone Oxoid L40
40g (D)-Glucose ACE G0979NN00.500
d.H2O
0.05 g chloramphenicol
 Dissolve in 1L d.H2O.
2. Semi solid agar vials
Nutrient broth N2 (Oxoid CM67) 25g
Bitek agar (Difco 214530) 9g
Deionized water make up to 1L
Buffers
Otherwise stated, all buffers were autoclaved.
1. Phosphate buffered saline (PBS) (1L)
10.7g Na2HPO4
2.72g KH2PO4
8.5g NaCl
d.H2O
Dissolve and make up to 1L with d.H2O
2. Normal Saline (1L)
 8.5g Sodium chloride
d.H2O 
Dissolve all in 1L d.H2O
3. TE Buffer
10mM Tris-Cl
1mM EDTA, pH 8.0
d.H2O
4. 1M Tris pH 8.0 (200ml)
24.2g Tris base
d.H2O
Dissolve powder in 150ml d.H2O. Add approximately 8.4 ml concentrated HCl for a solution
with a pH of 8.0, and check with a pH meter.
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5. 10% SDS (100ml)
10g SDS
d.H2O
Add SDS powder to d.H2O, and make up to 100mL. Heat at 68°C to dissolve the powder.
Adjust pH to 7.2 with 1M HCl. Do not autoclave.
6. 50x TAE buffer (100ml)
24.2g Tris base
5.7ml glacial acetic acid
10ml 0.5M EDTA (pH 8)
d.H2O
Dissolve Tris and EDTA.2H2O in d.H2O. Add the acetic acid and make up to 100ml with
d.H2O.
7. 5M Sodium Chloride (100ml)
29.2g NaCl
d.H2O
Dissolve powder in 100ml d.H2O and autoclave.
8. 0.5M EDTA (1L)
186.1g Na2EDTA.2H2O
d.H2O
Dissolve the Na2EDTA.2H2O powder in d.H2O, and adjust pH to 8.0 with 10M NaOH
(~50mL). Make up to 1L with d.H2O.
9. 10x TBE (400ml)
43.2g Tris base
22g Borate
16ml 0.5M EDTA
d.H2O
Dissolve in 400ml d.H2O.
10. 1M HCl (1L)
86.2mL concentrated HCl
d.H2O
Add 86.2ml concentrated HCl to 913.8ml d.H2O. Do not autoclave.
11. Sabouraud’s Dextrose Broth
10g Mycological Peptone Oxoid L40
40g (D)-Glucose ACE G0979NN00.500
d.H2O
Dissolve and make up to 1L with d.H2O.
12. 5M Potassium Acetate (80ml)
39.3g Potassium Acetate
d.H2O
Dissolve and make up to 80ml with d.H2O.
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Stains
1. Ethidium Bromide (10mg/ml) (10ml)
100mg Ethidium bromide
d.H2O
Make up to 10ml with d.H2O. Do not autoclave. Store in the dark
2. Gram’s Crystal Violet Stain
10g 90% crystal violet dye
500ml absolute Ethanol
3. Gram’s Iodine
6g Iodine
12g KI
1800ml distilled water
4. Gram’s Decolourizer
400ml acetone
1200ml 95% Ethanol
5. Gram’s Safranin
10g safranin dye
1000ml distilled water
6. Light Green Solution
1g Light Green dye
0.25ml Acetic acid
100ml 80% Ethanol
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Appendix C: List of Enzymes and Manufacturers
Enzyme Manufacturer
Lyticase Roche Applied Science
Proteinase K Roche Applied Science
RNase A Roche Applied Science
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Appendix D: Subject Information Form and Consent Form
Subject Information Sheet
Good day.
My name is Bintou Ahmadou Ahidjo. I am a student in the Department of Clinical
Microbiology and Infectious Diseases at the University of the Witwatersrand, where I am
currently doing research for my Master’s degree. For my research, I have chosen to study the
fungus called Candida. This causes candidiasis, which is also known as thrush, and is a
common infection.
Most people who are infected with HIV/AIDS have thrush. This is usually seen as a
white/cream mucous in the mouth and throat of individuals. Recently, a drug called 5-
fluorouracil, a drug used for the treatment of cancer, has been found to make thrush difficult
to treat. I want to know if antiretrovirals also make thrush difficult to treat. If it does, then
better treatment for people infected with HIV/AIDS will be needed. I would be very grateful
if you could help me with this research.
For this research, a bit of the white mucous needs to be taken from your mouth before you
begin antiretroviral treatment. This will be done by a qualified doctor, with a sterile cotton
bud, so that no other infection occurs.
This process will however cause slight discomfort and a small amount of bleeding. This is
because the mucous is attached to the mouth.
This is a once-only procedure, and none of this will be of an additional cost to you.
Participation is completely voluntary and not taking part will in no way affect the treatment
you will be receiving. Also, you can withdraw from this procedure at anytime without any
explanation, and this too will not affect the treatment you will be receiving.
Unfortunately, none of the results obtained from the research with your sample will be
reported back to you because to maintain confidentiality none of your details for example
name or hospital number will be recorded.
Thank you very much for your cooperation,
Yours Sincerely,
B. Ahmadou Ahidjo
Informed Consent Form
I ..................................................................., hereby agree to have mouth/oral swabs taken
from me by a qualified doctor at no additional cost to me. I understand that none of the
results obtained will be reported back to me.
I also understand that participation is completely voluntary, and that I can withdraw at
anytime without any explanation and this will not affect the treatment I will be receiving.
……………………………………                                        ……………………….
            (Signature)                                              (Date)
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Appendix F: Data Points
The data points obtained for each of virulence assay for each clinical isolate exposed to each
NRTI at 3 different concentrations at two time points and for two different occasions are
tabulated below.
Legend: Time 1: 24h exposure; Time 2: 72h exposure;
 NRTI 1: ddI, NRTI 2: 3TC; NRTI 3: d4T; NRTI 4: AZT
Concentration 0: No NRTI i.e. control; Concentration 1: Peak concentration of
NRTI; concentration 2: 2x Peak concentration of NRTI; Concentration 3: _ Peak
concentration of NRTI.
The values obtained for each replicate was the average of the duplicates.
The blanks in the table indicate where the assay was not performed. This could have been
due to delays in obtaining reagents from their respective manufacturers.
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Table: Experimental Data Obtained for the virulence traits of each isolate
Pat_Id Time NRTI Concentration Replicate Proliferation Assay Biofilm Assay Adherence Assay
1 1 1 0 1 1.632 0
1 1 1 0 2 2.927 0
1 1 1 1 1 1.3625 -19.65995802
1 1 1 1 2 1.573 -16.83078866
1 1 1 2 1 1.4745 1.361997208
1 1 1 2 2 1.682 -3.902678641
1 1 1 3 1
1 1 1 3 2
1 1 2 0 1 1.632 0
1 1 2 0 2 2.927 0
1 1 2 1 1 1.376 -13.79791841
1 1 2 1 2 1.738 -10.52478909
1 1 2 2 1 1.462 2.345762613
1 1 2 2 2 1.715 -13.95949199
1 1 2 3 1
1 1 2 3 2
1 1 3 0 1 1.632 0
1 1 3 0 2 2.927 0
1 1 3 1 1 1.3985 -6.02387212
1 1 3 1 2 1.6935 -16.94236116
1 1 3 2 1 1.44 10.8622474
1 1 3 2 2 1.6165 -11.49834351
1 1 3 3 1
1 1 3 3 2
1 1 4 0 1 0
1 1 4 0 2 2.927 0
1 1 4 1 1
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1 1 4 1 2 1.5895 -54.48666915
1 1 4 2 1
1 1 4 2 2 1.769 -17.8872717
1 1 4 3 1
1 1 4 3 2
1 2 1 0 1 2.25 0
1 2 1 0 2 1.8465 0
1 2 1 1 1 1.308 18.62137967
1 2 1 1 2 1.462 -0.899293086
1 2 1 2 1 1.3325 2.914316942
1 2 1 2 2 1.3135 3.570229792
1 2 1 3 1
1 2 1 3 2
1 2 2 0 1 2.25 0
1 2 2 0 2 1.8465 0
1 2 2 1 1 1.269 20.61283355
1 2 2 1 2 1.243 2.605582474
1 2 2 2 1 1.471 12.97937968
1 2 2 2 2 1.2735 3.907499465
1 2 2 3 1
1 2 2 3 2
1 2 3 0 1 2.25 0
1 2 3 0 2 1.8465 0
1 2 3 1 1 1.264 15.08816864
1 2 3 1 2 1.2665 1.37189937
1 2 3 2 1 1.282 -0.923358588
1 2 3 2 2 1.279 2.164525924
1 2 3 3 1
1 2 3 3 2
1 2 4 0 1 0
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1 2 4 0 2 1.8465 0
1 2 4 1 1
1 2 4 1 2 1.283 1.489478781
1 2 4 2 1
1 2 4 2 2 1.225 -2.697006302
1 2 4 3 1
1 2 4 3 2
2 1 1 0 1 1.7245 0
2 1 1 0 2 2.927 0
2 1 1 1 1 1.514 18.07016936
2 1 1 1 2 1.493 16.01953233
2 1 1 2 1 1.377 4.523579123
2 1 1 2 2 1.4635 15.63402526
2 1 1 3 1
2 1 1 3 2
2 1 2 0 1 1.7245 0
2 1 2 0 2 2.927 0
2 1 2 1 1 1.4395 16.84184854
2 1 2 1 2 1.559 15.39950512
2 1 2 2 1 1.4885 9.494638324
2 1 2 2 2 1.522 16.04499686
2 1 2 3 1
2 1 2 3 2
2 1 3 0 1 1.7245 0
2 1 3 0 2 2.927 0
2 1 3 1 1 1.384 26.26331533
2 1 3 1 2 1.54 12.94470763
2 1 3 2 1 1.4615 5.162629225
2 1 3 2 2 1.513 20.91195852
2 1 3 3 1
Appendices
103
2 1 3 3 2
2 1 4 0 1 2.927 0
2 1 4 0 2 0
2 1 4 1 1
2 1 4 1 2 1.557 9.738597578
2 1 4 2 1
2 1 4 2 2 1.561 9.966650115
2 1 4 3 1
2 1 4 3 2
2 2 1 0 1 1.632 0
2 2 1 0 2 1.5305 0
2 2 1 1 1 1.3625 -40.50462154
2 2 1 1 2 1.4285 16.82411803
2 2 1 2 1 1.4745 -28.62450002
2 2 1 2 2 1.47 20.74324856
2 2 1 3 1
2 2 1 3 2
2 2 2 0 1 1.632 0
2 2 2 0 2 1.5305 0
2 2 2 1 1 1.376 -36.55774183
2 2 2 1 2 2.165 23.50653813
2 2 2 2 1 1.462 -36.4106069
2 2 2 2 2 2.2635 10.72409062
2 2 2 3 1
2 2 2 3 2
2 2 3 0 1 1.632 0
2 2 3 0 2 1.5305 0
2 2 3 1 1 1.3985 -36.19053876
2 2 3 1 2 2.147 19.06761516
2 2 3 2 1 1.44 -3.274478165
Appendices
104
2 2 3 2 2 1.999 22.0726083
2 2 3 3 1
2 2 3 3 2
2 2 4 0 1 0
2 2 4 0 2 1.5305 0
2 2 4 1 1
2 2 4 1 2 2.1585 16.70501953
2 2 4 2 1
2 2 4 2 2 2.0395 15.57653846
2 2 4 3 1
2 2 4 3 2
3 1 1 0 1 0.9435 0 259
3 1 1 0 2 0.87 0
3 1 1 1 1 0.789 -13.83156304 84
3 1 1 1 2 0.7805 -10.80454161
3 1 1 2 1 0.7495 -10.47064773 52
3 1 1 2 2 0.8635 -14.02687337
3 1 1 3 1 0.7985 -4.311599637 39
3 1 1 3 2 0.857 50.47679705
3 1 2 0 1 0.9435 0 259
3 1 2 0 2 0.87 0
3 1 2 1 1 0.856 -23.31595225 95
3 1 2 1 2 0.8635 -3.362766992
3 1 2 2 1 1.389 -19.66621985 74
3 1 2 2 2 1.492 -0.805993019
3 1 2 3 1 0.878 -23.02469469 69
3 1 2 3 2 0.864 -1.69697802
3 1 3 0 1 0.9435 0 259
3 1 3 0 2 0.87 0
3 1 3 1 1 0.827 -29.43506492 350
Appendices
105
3 1 3 1 2 0.8255 -8.29075427
3 1 3 2 1 0.8315 -24.47025688 180
3 1 3 2 2 0.833 -1.398614262
3 1 3 3 1 0.7425 -32.99486995 90
3 1 3 3 2 0.8155 -1.473076437
3 1 4 0 1 0.9435 0 259
3 1 4 0 2 0.87 0
3 1 4 1 1 0.9415 -28.87222733 185
3 1 4 1 2 0.859 4.694811506
3 1 4 2 1 0.859 -26.62239894 361
3 1 4 2 2 0.8805 -0.365095346
3 1 4 3 1 0.9465 -25.12097297 280
3 1 4 3 2 0.8925 6.812491003
3 2 1 0 1 1.2855 0 265
3 2 1 0 2 1.2635 0
3 2 1 1 1 1.003 -14.07745595 31
3 2 1 1 2 1.042 -12.63147633
3 2 1 2 1 1.222 -14.15856273 77
3 2 1 2 2 1.2105 -10.97763334
3 2 1 3 1 1.197 -3.399555889 33
3 2 1 3 2 0.9355 -1.606567479
3 2 2 0 1 1.2855 0 265
3 2 2 0 2 1.2635 0
3 2 2 1 1 1.402 -21.50256426 70
3 2 2 1 2 1.1145 -3.876514235
3 2 2 2 1 1.71 -21.21957027 76
3 2 2 2 2 1.9445 -0.845610277
3 2 2 3 1 1.342 -7.774740876 54
3 2 2 3 2 1.1655 0.573027223
3 2 3 0 1 1.2855 0 265
Appendices
106
3 2 3 0 2 1.2635 0
3 2 3 1 1 1.654 -32.22622885 259
3 2 3 1 2 1.1365 6.065261753
3 2 3 2 1 1.325 -27.02667141 350
3 2 3 2 2 1.1945 -19.74297079
3 2 3 3 1 1.267 -31.46710643 135
3 2 3 3 2 1.1805 -2.220881875
3 2 4 0 1 1.2855 0 265
3 2 4 0 2 1.2635 0
3 2 4 1 1 1.526 -10.1111783 274
3 2 4 1 2 1.1775 1.463206117
3 2 4 2 1 1.423 -1.688672495 145
3 2 4 2 2 1.128 3.081885407
3 2 4 3 1 1.4955 -9.320464574 365
3 2 4 3 2 1.174 3.250416542
4 1 1 0 1 1.0435 0 160
4 1 1 0 2 1.013 0
4 1 1 1 1 0.822 -44.67176112 218
4 1 1 1 2 0.8325 10.76972329
4 1 1 2 1 1.0115 -46.72848151 368
4 1 1 2 2 0.911 20.78867439
4 1 1 3 1 0.9505 -36.14174524 225
4 1 1 3 2 1.003 13.1647863
4 1 2 0 1 1.0435 0 160
4 1 2 0 2 1.013 0
4 1 2 1 1 0.9675 -35.73451708 90
4 1 2 1 2 0.953 15.23212079
4 1 2 2 1 1.6345 -32.89693458 195
4 1 2 2 2 1.5115 21.18033175
4 1 2 3 1 1.059 -25.29146203 175
Appendices
107
4 1 2 3 2 0.988 14.80612403
4 1 3 0 1 1.0435 0 160
4 1 3 0 2 1.013 0
4 1 3 1 1 0.9425 -46.8892555 96
4 1 3 1 2 0.874 3.318759278
4 1 3 2 1 0.9525 -43.58953396 40
4 1 3 2 2 0.957 34.32094751
4 1 3 3 1 1.0345 -41.84902518 156
4 1 3 3 2 0.966 2.82398593
4 1 4 0 1 1.0435 0 160
4 1 4 0 2 1.013 0
4 1 4 1 1 0.966 -49.51262964 35
4 1 4 1 2 0.9265 0.9176565
4 1 4 2 1 0.949 -32.51204354 60
4 1 4 2 2 0.859 57.68968656
4 1 4 3 1 0.989 -36.62041381 220
4 1 4 3 2 0.941 8.20605089
4 2 1 0 1 1.2925 0 170
4 2 1 0 2 1.2855 0
4 2 1 1 1 1.4635 -56.77943395 305
4 2 1 1 2 1.172 1.613098214
4 2 1 2 1 1.268 -52.64425531 85
4 2 1 2 2 1.136 -15.47499198
4 2 1 3 1 1.2735 -51.51476346 189
4 2 1 3 2 1.2085 5.141670452
4 2 2 0 1 1.2925 0 170
4 2 2 0 2 1.2855 0
4 2 2 1 1 1.316 -43.90929324 209
4 2 2 1 2 1.1405 -4.818737812
4 2 2 2 1 1.7925 -54.95459189 189
Appendices
108
4 2 2 2 2 2.2785 -6.896700837
4 2 2 3 1 1.35 -45.55618693 120
4 2 2 3 2 1.212 -1.258552087
4 2 3 0 1 1.2925 0 170
4 2 3 0 2 1.2855 0
4 2 3 1 1 1.3215 -42.60495104 55
4 2 3 1 2 1.1235 9.394678158
4 2 3 2 1 1.373 -53.79077917 100
4 2 3 2 2 1.354 3.484905025
4 2 3 3 1 1.3375 -50.40205063 140
4 2 3 3 2 1.1975 0.427725916
4 2 4 0 1 1.2925 0 170
4 2 4 0 2 1.2855 0
4 2 4 1 1 1.333 -52.99520597 130
4 2 4 1 2 1.1715 -8.97831989
4 2 4 2 1 1.4025 -49.80975993 100
4 2 4 2 2 1.319 0.805905389
4 2 4 3 1 1.4275 -45.31847161 180
4 2 4 3 2 1.214 0.266000896
5 1 1 0 1 0.6505 0 186
5 1 1 0 2 0.706 0
5 1 1 1 1 0.5605 6.166338301 83
5 1 1 1 2 0.682 -17.95749139
5 1 1 2 1 0.5055 1.872097806 40
5 1 1 2 2 0.6375 -10.28429855
5 1 1 3 1 0.5045 42.37983215 250
5 1 1 3 2 0.6635 26.95476686
5 1 2 0 1 0.6505 0 186
5 1 2 0 2 0.706 0
5 1 2 1 1 0.598 20.02862779 55
Appendices
109
5 1 2 1 2 0.657 -15.67959945
5 1 2 2 1 1.1555 9.854462248 95
5 1 2 2 2 1.282 -5.414447587
5 1 2 3 1 0.7095 10.83439879 79
5 1 2 3 2 0.737 1.126913787
5 1 3 0 1 0.6505 0 186
5 1 3 0 2 0.706 0
5 1 3 1 1 0.6945 0.693954954 67
5 1 3 1 2 0.7415 0.454661407
5 1 3 2 1 0.594 29.46983816 99
5 1 3 2 2 0.6985 -1.395817164
5 1 3 3 1 0.662 -2.201366416 75
5 1 3 3 2 0.715 3.159675786
5 1 4 0 1 0.6505 0 186
5 1 4 0 2 0.706 0
5 1 4 1 1 0.504 -3.807977468 160
5 1 4 1 2 0.6875 -16.19219781
5 1 4 2 1 0.658 -3.267500471 50
5 1 4 2 2 0.6385 -15.61585597
5 1 4 3 1 0.5855 4.561754038 95
5 1 4 3 2 0.7265 -18.55822253
5 2 1 0 1 0.674 0 115
5 2 1 0 2 1.0955 0
5 2 1 1 1 0.5855 -22.49303179 85
5 2 1 1 2 1.065 -23.17635547
5 2 1 2 1 0.4445 -13.25200114 78
5 2 1 2 2 1.097 -14.61398444
5 2 1 3 1 0.585 33.68713943 125
5 2 1 3 2 1.175 37.93468274
5 2 2 0 1 0.674 0 115
Appendices
110
5 2 2 0 2 1.0955 0
5 2 2 1 1 0.5945 22.35247324 75
5 2 2 1 2 1.1775 -14.23909233
5 2 2 2 1 1.185 28.95306064 245
5 2 2 2 2 1.3365 -8.117540587
5 2 2 3 1 0.7055 25.14562185 125
5 2 2 3 2 1.2375 -16.67611872
5 2 3 0 1 0.674 0 115
5 2 3 0 2 1.0955 0
5 2 3 1 1 0.586 19.06733118 150
5 2 3 1 2 1.1195 -10.32483484
5 2 3 2 1 0.431 20.86566865 40
5 2 3 2 2 0.9605 -15.98160609
5 2 3 3 1 0.6845 25.93990573 170
5 2 3 3 2 1.0495 -15.06671291
5 2 4 0 1 0.674 0 115
5 2 4 0 2 1.0955 0
5 2 4 1 1 0.468 -0.214410509 170
5 2 4 1 2 0.8775 -3.376361467
5 2 4 2 1 0.548 6.040490071 90
5 2 4 2 2 1.2315 -18.00777317
5 2 4 3 1 0.4895 -6.453872199 15
5 2 4 3 2 1.0195 -15.75169646
6 1 1 0 1 0.6625 0 160
6 1 1 0 2 0.5185 0
6 1 1 1 1 0.618 1.332525992 180
6 1 1 1 2 0.7275 -12.23245107
6 1 1 2 1 0.6705 6.118968829 160
6 1 1 2 2 0.705 -1.96197907
6 1 1 3 1 0.7085 0.632378786 378
Appendices
111
6 1 1 3 2 0.782 15.64749376
6 1 2 0 1 0.6625 0 160
6 1 2 0 2 0.5185 0
6 1 2 1 1 0.624 4.391429247 275
6 1 2 1 2 0.711 -1.441944339
6 1 2 2 1 1.5395 5.598465769 212
6 1 2 2 2 1.5375 0.260481698
6 1 2 3 1 0.7345 5.361505652 360
6 1 2 3 2 0.748 1.153504461
6 1 3 0 1 0.6625 0 160
6 1 3 0 2 0.5185 0
6 1 3 1 1 0.5495 -4.4270208 70
6 1 3 1 2 0.535 -3.761743477
6 1 3 2 1 0.641 3.769566745 165
6 1 3 2 2 0.707 -10.22481586
6 1 3 3 1 0.661 6.682478345 455
6 1 3 3 2 0.78 0.582728111
6 1 4 0 1 0.6625 0 160
6 1 4 0 2 0.5185 0
6 1 4 1 1 0.554 4.992496803 350
6 1 4 1 2 0.648 2.169696416
6 1 4 2 1 0.597 1.192828667 585
6 1 4 2 2 0.718 20.55047994
6 1 4 3 1 0.652 0.617674779 150
6 1 4 3 2 0.5395 1.247489161
6 2 1 0 1 0.386 0 157
6 2 1 0 2 0.7715 0
6 2 1 1 1 1.297 7.979219089 395
6 2 1 1 2 0.853 -5.452920604
6 2 1 2 1 1.22 10.80514085 375
Appendices
112
6 2 1 2 2 0.789 2.786341354
6 2 1 3 1 1.0875 10.54334306 228
6 2 1 3 2 0.899 7.280332186
6 2 2 0 1 0.386 0 157
6 2 2 0 2 0.7715 0
6 2 2 1 1 1.2105 -13.54757303 258
6 2 2 1 2 0.8595 5.355457497
6 2 2 2 1 1.241 6.500351896 275
6 2 2 2 2 0.9075 7.280332186
6 2 2 3 1 1.207 2.70143202 720
6 2 2 3 2 0.9695 10.18192542
6 2 3 0 1 0.386 0 157
6 2 3 0 2 0.7715 0
6 2 3 1 1 1.335 -4.811277151 225
6 2 3 1 2 0.847 4.538712406
6 2 3 2 1 1.229 0.713373451 130
6 2 3 2 2 0.9225 9.512983402
6 2 3 3 1 1.279 2.725142247 210
6 2 3 3 2 0.953 9.609538946
6 2 4 0 1 0.386 0 157
6 2 4 0 2 0.7715 0
6 2 4 1 1 1.0925 4.579360323 160
6 2 4 1 2 0.8095 9.079938312
6 2 4 2 1 1.1555 8.4996086 147
6 2 4 2 2 0.8545 -4.165570194
6 2 4 3 1 1.1935 -9.881714602 192
6 2 4 3 2 0.8985 0.16089217
7 1 1 0 1 0.609 0 198
7 1 1 0 2 0.848 0
7 1 1 1 1 0.4825 8.107906557 12
Appendices
113
7 1 1 1 2 0.8265 -3.47202861
7 1 1 2 1 0.512 4.949989044 150
7 1 1 2 2 0.7535 -2.332863872
7 1 1 3 1 0.5375 3.290904334 240
7 1 1 3 2 0.8105 -6.36368791
7 1 2 0 1 0.609 0 198
7 1 2 0 2 0.848 0
7 1 2 1 1 0.599 -5.097201318 210
7 1 2 1 2 0.6015 4.239618679
7 1 2 2 1 0.595 -0.708815358 295
7 1 2 2 2 0.7725 6.831152995
7 1 2 3 1 0.6255 -9.033894354 310
7 1 2 3 2 0.936 4.773804476
7 1 3 0 1 0.609 0 198
7 1 3 0 2 0.848 0
7 1 3 1 1 0.4645 0.431141653 525
7 1 3 1 2 0.76 5.623744878
7 1 3 2 1 0.5555 1.892351082 125
7 1 3 2 2 0.82 1.786991413
7 1 3 3 1 0.5395 -4.588778208 84
7 1 3 3 2 0.8035 3.192800067
7 1 4 0 1 0.609 0 198
7 1 4 0 2 0.848 0
7 1 4 1 1 0.454 -2.463011162 325
7 1 4 1 2 0.783 -1.433290107
7 1 4 2 1 0.5465 1.571010209 308
7 1 4 2 2 0.774 0.916635717
7 1 4 3 1 0.53 2.498435501 360
7 1 4 3 2 0.819 8.051001622
7 2 1 0 1 0.5075 0 105
Appendices
114
7 2 1 0 2 0.616 0
7 2 1 1 1 1.1785 -3.919745989 144
7 2 1 1 2 0.534 -5.440532233
7 2 1 2 1 1.1305 -17.6302107 85
7 2 1 2 2 0.5695 -1.833416026
7 2 1 3 1 1.144 -5.886163302 330
7 2 1 3 2 0.6245 -2.720748822
7 2 2 0 1 0.5075 0 105
7 2 2 0 2 0.616 0
7 2 2 1 1 1.082 0.80677771 342
7 2 2 1 2 0.727 -5.485636309
7 2 2 2 1 1.2485 1.665536498 302
7 2 2 2 2 0.7155 -7.452068645
7 2 2 3 1 1.337 1.819292217 162
7 2 2 3 2 0.7655 -7.526723347
7 2 3 0 1 0.5075 0 105
7 2 3 0 2 0.616 0
7 2 3 1 1 1.128 -1.374550849 330
7 2 3 1 2 0.602 -3.925571925
7 2 3 2 1 1.339 2.727751586 215
7 2 3 2 2 0.653 1.198308438
7 2 3 3 1 1.3375 -5.547683819 100
7 2 3 3 2 0.625 -11.19674091
7 2 4 0 1 0.5075 0 105
7 2 4 0 2 0.616 0
7 2 4 1 1 1.157 -8.555286139 335
7 2 4 1 2 0.5415 -2.318341786
7 2 4 2 1 1.223 -4.209026003 150
7 2 4 2 2 0.5965 1.593963697
7 2 4 3 1 1.348 1.060227273 102
Appendices
115
7 2 4 3 2 0.6175 -1.132708502
8 1 1 0 1 0.29 0 242
8 1 1 0 2 0.6575 0
8 1 1 1 1 0.1765 -39.96469832 285
8 1 1 1 2 0.882 -7.030874857
8 1 1 2 1 0.3025 -11.22599082 265
8 1 1 2 2 0.7605 -0.67925543
8 1 1 3 1 0.312 11.6137201 425
8 1 1 3 2 0.8615 3.755229894
8 1 2 0 1 0.29 0 242
8 1 2 0 2 0.6575 0
8 1 2 1 1 0.2925 -8.507054904 296
8 1 2 1 2 0.76 1.031451793
8 1 2 2 1 1.404 -6.276798611 445
8 1 2 2 2 1.4515 3.029989156
8 1 2 3 1 0.453 -2.880269206 390
8 1 2 3 2 0.882 1.436191877
8 1 3 0 1 0.29 0 242
8 1 3 0 2 0.6575 0
8 1 3 1 1 0.2735 -9.780486885 110
8 1 3 1 2 0.689 3.107418628
8 1 3 2 1 0.3645 -12.64731236 250
8 1 3 2 2 0.8735 2.442945699
8 1 3 3 1 0.3945 -7.758497203 230
8 1 3 3 2 0.822 -2.360295509
8 1 4 0 1 0.29 0 242
8 1 4 0 2 0.6575 0
8 1 4 1 1 0.3535 -13.46615029 117
8 1 4 1 2 0.756 3.107418628
8 1 4 2 1 0.3405 -14.30309728 315
Appendices
116
8 1 4 2 2 0.795 2.329042765
8 1 4 3 1 0.4045 -10.05688489 195
8 1 4 3 2 0.774 2.377970732
8 2 1 0 1 0.815 0 430
8 2 1 0 2 0.516 0
8 2 1 1 1 0.6585 -1.394502525 370
8 2 1 1 2 1.007 -1.93054689
8 2 1 2 1 0.766 -1.2294891 445
8 2 1 2 2 0.704 -1.632604796
8 2 1 3 1 0.761 -10.09445732 640
8 2 1 3 2 0.82 -11.09329747
8 2 2 0 1 0.815 0 430
8 2 2 0 2 0.516 0
8 2 2 1 1 0.7355 -0.003075642 368
8 2 2 1 2 0.742 -2.374668303
8 2 2 2 1 1.48 -0.161461229 225
8 2 2 2 2 1.321 -1.273331019
8 2 2 3 1 0.693 -2.411663658 705
8 2 2 3 2 0.687 -2.416806907
8 2 3 0 1 0.815 0 430
8 2 3 0 2 0.516 0
8 2 3 1 1 0.8905 -0.562282436 1560
8 2 3 1 2 0.6465 -1.678563777
8 2 3 2 1 0.7535 -1.66018991 601
8 2 3 2 2 0.6895 -1.394400065
8 2 3 3 1 0.664 -1.625433501 385
8 2 3 3 2 0.656 -0.588345156
8 2 4 0 1 0.815 0 430
8 2 4 0 2 0.516 0
8 2 4 1 1 0.7335 -0.540032037 345
Appendices
117
8 2 4 1 2 0.478 -2.170401977
8 2 4 2 1 0.688 0.461926034 138
8 2 4 2 2 0.528 -1.433468974
8 2 4 3 1 0.667 0.95597346 365
8 2 4 3 2 0.563 -0.572791309
9 1 1 0 1 0.7745 0 430
9 1 1 0 2 0.8525 0
9 1 1 1 1 0.8105 -7.139678049 630
9 1 1 1 2 1.161 -1.301198291
9 1 1 2 1 0.8245 -16.57210784 460
9 1 1 2 2 1.058 1.466418478
9 1 1 3 1 0.8665 -3.780204688 232
9 1 1 3 2 0.941 2.009891451
9 1 2 0 1 0.7745 0 430
9 1 2 0 2 0.8525 0
9 1 2 1 1 0.8255 -7.364417929 455
9 1 2 1 2 1.098 0.655575124
9 1 2 2 1 0.8715 -3.080858299 237
9 1 2 2 2 1.0355 -0.881838745
9 1 2 3 1 0.8685 0.932597764 280
9 1 2 3 2 0.9415 -1.458557276
9 1 3 0 1 0.7745 0 430
9 1 3 0 2 0.8525 0
9 1 3 1 1 0.8275 -4.118902051 512
9 1 3 1 2 1.0575 0.683164766
9 1 3 2 1 0.85 -12.85201179 435
9 1 3 2 2 0.9835 -3.525518668
9 1 3 3 1 0.8915 1.614460216 408
9 1 3 3 2 0.919 -2.089442539
9 1 4 0 1 0.7745 0 430
Appendices
118
9 1 4 0 2 0.8525 0
9 1 4 1 1 0.82 -4.904172543 465
9 1 4 1 2 1.088 0.15909831
9 1 4 2 1 0.8285 0.963658789 345
9 1 4 2 2 0.972 -2.376099524
9 1 4 3 1 0.7475 -1.539409248 265
9 1 4 3 2 0.8955 -0.881838745
9 2 1 0 1 1.002 0 440
9 2 1 0 2 1.0635 0
9 2 1 1 1 0.981 -0.800549722 527
9 2 1 1 2 0.9145 0.632604362
9 2 1 2 1 1.0935 -0.917307026 432
9 2 1 2 2 1.002 1.694891574
9 2 1 3 1 0.987 -0.15122788 668
9 2 1 3 2 1.001 0.773635479
9 2 2 0 1 1.002 0 440
9 2 2 0 2 1.0635 0
9 2 2 1 1 1.1345 -0.977733226 295
9 2 2 1 2 1.057 1.497224972
9 2 2 2 1 1.105 -0.686325063 285
9 2 2 2 2 1.03 0.868056404
9 2 2 3 1 1.1225 0.032500613 305
9 2 2 3 2 0.976 1.121729903
9 2 3 0 1 1.002 0 440
9 2 3 0 2 1.0635 0
9 2 3 1 1 1.1375 -0.439051349 510
9 2 3 1 2 0.941 1.266618891
9 2 3 2 1 1.0735 0.460686335 405
9 2 3 2 2 0.9825 1.415494056
9 2 3 3 1 1.2425 0.144021129 165
Appendices
119
9 2 3 3 2 1.0595 0.846335875
9 2 4 0 1 1.002 0 440
9 2 4 0 2 1.0635 0
9 2 4 1 1 1.013 -0.232980923 200
9 2 4 1 2 0.953 0.828004794
9 2 4 2 1 1.062 0.026811334 275
9 2 4 2 2 0.9185 0.790703381
9 2 4 3 1 1.0505 0.293305957 475
9 2 4 3 2 0.87 0.893020649
10 1 1 0 1 190
10 1 1 0 2
10 1 1 1 1 156
10 1 1 1 2
10 1 1 2 1 304
10 1 1 2 2
10 1 1 3 1 230
10 1 1 3 2
10 1 2 0 1 190
10 1 2 0 2
10 1 2 1 1 75
10 1 2 1 2
10 1 2 2 1 280
10 1 2 2 2
10 1 2 3 1 35
10 1 2 3 2
10 1 3 0 1 190
10 1 3 0 2
10 1 3 1 1 372
10 1 3 1 2
10 1 3 2 1 185
Appendices
120
10 1 3 2 2
10 1 3 3 1 290
10 1 3 3 2
10 1 4 0 1 190
10 1 4 0 2
10 1 4 1 1 95
10 1 4 1 2
10 1 4 2 1 356
10 1 4 2 2
10 1 4 3 1 190
10 1 4 3 2
10 2 1 0 1 165
10 2 1 0 2
10 2 1 1 1 340
10 2 1 1 2
10 2 1 2 1 340
10 2 1 2 2
10 2 1 3 1 757
10 2 1 3 2
10 2 2 0 1 165
10 2 2 0 2
10 2 2 1 1 657
10 2 2 1 2
10 2 2 2 1 600
10 2 2 2 2
10 2 2 3 1 300
10 2 2 3 2
10 2 3 0 1 165
10 2 3 0 2
10 2 3 1 1 55
Appendices
121
10 2 3 1 2
10 2 3 2 1 160
10 2 3 2 2
10 2 3 3 1 805
10 2 3 3 2
10 2 4 0 1 165
10 2 4 0 2
10 2 4 1 1 155
10 2 4 1 2
10 2 4 2 1 285
10 2 4 2 2
10 2 4 3 1 402
10 2 4 3 2
11 1 1 0 1 280
11 1 1 0 2
11 1 1 1 1 20
11 1 1 1 2
11 1 1 2 1 84
11 1 1 2 2
11 1 1 3 1 265
11 1 1 3 2
11 1 2 0 1 280
11 1 2 0 2
11 1 2 1 1 335
11 1 2 1 2
11 1 2 2 1 315
11 1 2 2 2
11 1 2 3 1 90
11 1 2 3 2
11 1 3 0 1 280
Appendices
122
11 1 3 0 2
11 1 3 1 1 78
11 1 3 1 2
11 1 3 2 1 412
11 1 3 2 2
11 1 3 3 1 260
11 1 3 3 2
11 1 4 0 1 280
11 1 4 0 2
11 1 4 1 1 30
11 1 4 1 2
11 1 4 2 1 480
11 1 4 2 2
11 1 4 3 1 290
11 1 4 3 2
11 2 1 0 1 620
11 2 1 0 2
11 2 1 1 1 562
11 2 1 1 2
11 2 1 2 1 95
11 2 1 2 2
11 2 1 3 1 140
11 2 1 3 2
11 2 2 0 1 620
11 2 2 0 2
11 2 2 1 1 540
11 2 2 1 2
11 2 2 2 1 215
11 2 2 2 2
11 2 2 3 1 210
Appendices
123
11 2 2 3 2
11 2 3 0 1 620
11 2 3 0 2
11 2 3 1 1 515
11 2 3 1 2
11 2 3 2 1 340
11 2 3 2 2
11 2 3 3 1 640
11 2 3 3 2
11 2 4 0 1 620
11 2 4 0 2
11 2 4 1 1 161
11 2 4 1 2
11 2 4 2 1 360
11 2 4 2 2
11 2 4 3 1 315
11 2 4 3 2
12 1 1 0 1 0.7785 0 316
12 1 1 0 2 0
12 1 1 1 1 0.8475 -5.910056445 120
12 1 1 1 2 -4.803929611
12 1 1 2 1 0.7935 -6.50778489 484
12 1 1 2 2 -2.884940813
12 1 1 3 1 0.8255 -5.651001703 132
12 1 1 3 2 -0.334346496
12 1 2 0 1 0.7785 0 316
12 1 2 0 2 0
12 1 2 1 1 0.8905 2.048355491 198
12 1 2 1 2 -0.228465399
12 1 2 2 1 1.3745 2.664084191 342
Appendices
124
12 1 2 2 2 -1.510482564
12 1 2 3 1 0.832 2.735268308 290
12 1 2 3 2 -0.775357001
12 1 3 0 1 0.7785 0 316
12 1 3 0 2 0
12 1 3 1 1 0.858 -4.804370307 96
12 1 3 1 2 0.09340779
12 1 3 2 1 0.812 6.441987335 210
12 1 3 2 2 5.273907155
12 1 3 3 1 0.802 5.515012843 215
12 1 3 3 2 -1.065781414
12 1 4 0 1 0.7785 0 316
12 1 4 0 2 0
12 1 4 1 1 0.848 -3.38337042 1135
12 1 4 1 2 0.44664647
12 1 4 2 1 0.7525 -1.63276427 265
12 1 4 2 2 0.867809637
12 1 4 3 1 0.712 -3.458504644 1100
12 1 4 3 2 -1.05732014
12 2 1 0 1 0.829 0 1020
12 2 1 0 2 0
12 2 1 1 1 0.8055 -0.890100692 200
12 2 1 1 2 2.159450344
12 2 1 2 1 0.8625 -3.765219649 930
12 2 1 2 2 8.375292821
12 2 1 3 1 0.815 -11.557964 350
12 2 1 3 2 1.536176348
12 2 2 0 1 0.829 0 1020
12 2 2 0 2 0
12 2 2 1 1 0.9075 -1.293921273 760
Appendices
125
12 2 2 1 2 3.127218219
12 2 2 2 1 1.518 -2.49185771 660
12 2 2 2 2 4.124205753
12 2 2 3 1 0.8395 -1.919655279 520
12 2 2 3 2 2.404939955
12 2 3 0 1 0.829 0 1020
12 2 3 0 2 0
12 2 3 1 1 0.8435 -1.31125284 770
12 2 3 1 2 1.295834977
12 2 3 2 1 0.791 -1.200708431 580
12 2 3 2 2 7.361381436
12 2 3 3 1 0.699 -1.340406164 920
12 2 3 3 2 1.336470542
12 2 4 0 1 0.829 0 1020
12 2 4 0 2 0
12 2 4 1 1 0.7355 -1.299685165 700
12 2 4 1 2 3.730140069
12 2 4 2 1 0.8135 -1.319963622 750
12 2 4 2 2 3.632872969
12 2 4 3 1 0.8105 -1.841470901 1140
12 2 4 3 2 1.55190588
13 1 1 0 1 0.927 0 2020
13 1 1 0 2 0
13 1 1 1 1 0.919 -7.086076232 1750
13 1 1 1 2 0.83854864
13 1 1 2 1 0.8905 -4.939744808 1510
13 1 1 2 2 -0.349083382
13 1 1 3 1 0.8905 -10.51792131 1800
13 1 1 3 2 -9.146126181
13 1 2 0 1 0.927 0 2020
Appendices
126
13 1 2 0 2 0
13 1 2 1 1 0.9255 -1.252984894 2400
13 1 2 1 2 -0.004168077
13 1 2 2 1 0.901 -0.640887003 5180
13 1 2 2 2 0.535073957
13 1 2 3 1 0.902 -0.205417678 2300
13 1 2 3 2 0.531522262
13 1 3 0 1 0.927 0 2020
13 1 3 0 2 0
13 1 3 1 1 0.874 -6.413176458 1750
13 1 3 1 2 -0.647533281
13 1 3 2 1 0.8695 -4.849310904 2420
13 1 3 2 2 -1.146047961
13 1 3 3 1 0.8875 -3.261610188 2100
13 1 3 3 2 -1.66011016
13 1 4 0 1 0.927 0 2020
13 1 4 0 2 0
13 1 4 1 1 0.8945 -5.975959723 1740
13 1 4 1 2 -4.805382007
13 1 4 2 1 0.9045 -5.183724603 2100
13 1 4 2 2 -3.626097693
13 1 4 3 1 0.913 -4.537754429 1700
13 1 4 3 2 -2.169357976
13 2 1 0 1 0.833 0 1780
13 2 1 0 2 0
13 2 1 1 1 0.8325 1.577066217 1780
13 2 1 1 2 -0.451671051
13 2 1 2 1 0.903 2.973778079 1200
13 2 1 2 2 0.481917453
13 2 1 3 1 0.8845 3.002474734 1980
Appendices
127
13 2 1 3 2 -9.688291273
13 2 2 0 1 0.833 0 1780
13 2 2 0 2 0
13 2 2 1 1 0.8435 1.123645131 2340
13 2 2 1 2 0.280336087
13 2 2 2 1 0.897 2.846987632 1460
13 2 2 2 2 1.183753196
13 2 2 3 1 0.853 3.193490238 1380
13 2 2 3 2 1.237442861
13 2 3 0 1 0.833 0 1780
13 2 3 0 2 0
13 2 3 1 1 0.846 0.688497649 1260
13 2 3 1 2 1.222565191
13 2 3 2 1 0.8265 4.240208765 700
13 2 3 2 2 1.373938306
13 2 3 3 1 0.8065 1.738515746 1320
13 2 3 3 2 0.17207416
13 2 4 0 1 0.833 0 1780
13 2 4 0 2 0
13 2 4 1 1 0.846 4.161422524 1500
13 2 4 1 2 -3.826301224
13 2 4 2 1 0.8225 3.518318888 1649
13 2 4 2 2 -0.730176761
13 2 4 3 1 0.916 -4.792037752 1084
13 2 4 3 2 -0.068029606
14 1 1 0 1 0 1120
14 1 1 0 2 0
14 1 1 1 1 -0.401499311 680
14 1 1 1 2 -1.254469225
14 1 1 2 1 2.244036202 1520
Appendices
128
14 1 1 2 2 0.216706
14 1 1 3 1 -5.037582237 1040
14 1 1 3 2 -9.772712482
14 1 2 0 1 0 1120
14 1 2 0 2 0
14 1 2 1 1 -3.390511422 1060
14 1 2 1 2 -0.09894885
14 1 2 2 1 3.270243367 880
14 1 2 2 2 -2.098059476
14 1 2 3 1 2.726460501 1040
14 1 2 3 2 -0.899150447
14 1 3 0 1 0 1120
14 1 3 0 2 0
14 1 3 1 1 2.840282258 1040
14 1 3 1 2 -0.704597963
14 1 3 2 1 4.475932877 1000
14 1 3 2 2 2.517920312
14 1 3 3 1 3.880888031 1160
14 1 3 3 2 0.224330577
14 1 4 0 1 0 1120
14 1 4 0 2 0
14 1 4 1 1 1.351515041 560
14 1 4 1 2 0.677529184
14 1 4 2 1 1.240461515 529
14 1 4 2 2 0.590798004
14 1 4 3 1 3.911757908 740
14 1 4 3 2 0.901563706
14 2 1 0 1 0 1440
14 2 1 0 2 0
14 2 1 1 1 -2.659041651 780
Appendices
129
14 2 1 1 2 -2.204870633
14 2 1 2 1 -1.414757154 1100
14 2 1 2 2 3.108881995
14 2 1 3 1 -3.189985689 1080
14 2 1 3 2 3.665363049
14 2 2 0 1 0 1440
14 2 2 0 2 0
14 2 2 1 1 -4.892204228 740
14 2 2 1 2 5.394293836
14 2 2 2 1 0.312148696 1420
14 2 2 2 2 6.354815633
14 2 2 3 1 -1.474989708 540
14 2 2 3 2 5.190420593
14 2 3 0 1 0 1440
14 2 3 0 2 0
14 2 3 1 1 -1.654612 420
14 2 3 1 2 3.396605772
14 2 3 2 1 2.297399829 2040
14 2 3 2 2 9.812885766
14 2 3 3 1 -1.196855831 1960
14 2 3 3 2 4.332980836
14 2 4 0 1 0 1440
14 2 4 0 2 0
14 2 4 1 1 -2.99826223 1800
14 2 4 1 2 8.297499155
14 2 4 2 1 -0.692743468 280
14 2 4 2 2 6.994139747
14 2 4 3 1 -0.434104256 720
14 2 4 3 2 -0.628332263
15 1 1 0 1 0 1460
Appendices
130
15 1 1 0 2 0
15 1 1 1 1 -0.538752623 480
15 1 1 1 2 -3.720924351
15 1 1 2 1 1.589605135 605
15 1 1 2 2 -1.37121189
15 1 1 3 1 1.583604244 263
15 1 1 3 2 -9.84023571
15 1 2 0 1 0 1460
15 1 2 0 2 0
15 1 2 1 1 -2.204588388 727
15 1 2 1 2 -0.648576004
15 1 2 2 1 -0.610100836 568
15 1 2 2 2 0.617405189
15 1 2 3 1 -0.495373855 640
15 1 2 3 2 0.147637532
15 1 3 0 1 0 1460
15 1 3 0 2 0
15 1 3 1 1 0.611795596 980
15 1 3 1 2 0.092760382
15 1 3 2 1 3.178848581 1600
15 1 3 2 2 -0.752901556
15 1 3 3 1 0.257259212 460
15 1 3 3 2 0.947182738
15 1 4 0 1 0 1460
15 1 4 0 2 0
15 1 4 1 1 -4.077135119 582
15 1 4 1 2 -0.698277606
15 1 4 2 1 -0.51159409 661
15 1 4 2 2 -0.39097332
15 1 4 3 1 -0.560592293 449
Appendices
131
15 1 4 3 2 -0.855918995
15 2 1 0 1 0 480
15 2 1 0 2 0
15 2 1 1 1 3.183890595 480
15 2 1 1 2 -2.324814808
15 2 1 2 1 3.049868855 660
15 2 1 2 2 2.160854069
15 2 1 3 1 -5.169873861 1113
15 2 1 3 2 -7.752515752
15 2 2 0 1 0 480
15 2 2 0 2 0
15 2 2 1 1 2.81922149 1053
15 2 2 1 2 1.179214932
15 2 2 2 1 2.906380405 447
15 2 2 2 2 0.404004649
15 2 2 3 1 1.793552501 573
15 2 2 3 2 0.203478852
15 2 3 0 1 0 480
15 2 3 0 2 0
15 2 3 1 1 4.06674636 1109
15 2 3 1 2 -5.592867047
15 2 3 2 1 3.792620263 780
15 2 3 2 2 -1.914406958
15 2 3 3 1 3.075954783 722
15 2 3 3 2 -4.097742186
15 2 4 0 1 0 480
15 2 4 0 2 0
15 2 4 1 1 4.550126237 1086
15 2 4 1 2 0.209011534
15 2 4 2 1 4.143076833 965
Appendices
132
15 2 4 2 2 -1.946377211
15 2 4 3 1 3.01309536 1180
15 2 4 3 2 -2.679432067
16 1 1 0 1 0 560
16 1 1 0 2 0
16 1 1 1 1 1.522877811 724
16 1 1 1 2 2.358529907
16 1 1 2 1 0.18024471 683
16 1 1 2 2 4.880396321
16 1 1 3 1 -7.082404173 1479
16 1 1 3 2 -4.282354264
16 1 2 0 1 0 560
16 1 2 0 2 0
16 1 2 1 1 2.49044606 1040
16 1 2 1 2 3.388725114
16 1 2 2 1 1.966631625 1164
16 1 2 2 2 4.834494355
16 1 2 3 1 2.26218949 1078
16 1 2 3 2 4.950202127
16 1 3 0 1 0 560
16 1 3 0 2 0
16 1 3 1 1 0.409685301 1660
16 1 3 1 2 4.318136614
16 1 3 2 1 1.215147994 247
16 1 3 2 2 4.146925041
16 1 3 3 1 0.553370076 615
16 1 3 3 2 2.620652179
16 1 4 0 1 0 560
16 1 4 0 2 0
16 1 4 1 1 0.511871336 740
Appendices
133
16 1 4 1 2 4.061242656
16 1 4 2 1 2.389679382 487
16 1 4 2 2 2.948532732
16 1 4 3 1 1.356845605 1129
16 1 4 3 2 1.635038994
16 2 1 0 1 0 300
16 2 1 0 2 0
16 2 1 1 1 -0.842676359 460
16 2 1 1 2 8.898242518
16 2 1 2 1 -1.038545478 1480
16 2 1 2 2 2.477002228
16 2 1 3 1 -4.253007706 385
16 2 1 3 2 2.215204442
16 2 2 0 1 0 300
16 2 2 0 2 0
16 2 2 1 1 4.783173533 974
16 2 2 1 2 8.720663891
16 2 2 2 1 4.652156266 946
16 2 2 2 2 -0.669890662
16 2 2 3 1 3.196420387 862
16 2 2 3 2 -1.426305202
16 2 3 0 1 0 300
16 2 3 0 2 0
16 2 3 1 1 4.230826186 280
16 2 3 1 2 1.112034242
16 2 3 2 1 -0.32959131 440
16 2 3 2 2 4.484168244
16 2 3 3 1 2.187261868 355
16 2 3 3 2 3.121905049
16 2 4 0 1 0 300
Appendices
134
16 2 4 0 2 0
16 2 4 1 1 2.194538589 467
16 2 4 1 2 4.640081521
16 2 4 2 1 4.437577604 189
16 2 4 2 2 9.658509938
16 2 4 3 1 3.730586721 274
16 2 4 3 2 0.83794528
17 1 1 0 1 0
17 1 1 0 2 0
17 1 1 1 1 1.505443298 466
17 1 1 1 2 1.360450022
17 1 1 2 1 1.807492761 623
17 1 1 2 2 0.751389944
17 1 1 3 1 0.916716488 1245
17 1 1 3 2 0.666643793
17 1 2 0 1 0 820
17 1 2 0 2 0
17 1 2 1 1 0.587562614 581
17 1 2 1 2 1.525787358
17 1 2 2 1 0.776813003 945
17 1 2 2 2 1.451930523
17 1 2 3 1 0.861334264 765
17 1 2 3 2 1.745680896
17 1 3 0 1 0 820
17 1 3 0 2 0
17 1 3 1 1 0.567667516 807
17 1 3 1 2 -0.345394124
17 1 3 2 1 3.883876808 689
17 1 3 2 2 3.041173969
17 1 3 3 1 1.16098694 1140
Appendices
135
17 1 3 3 2 0.373795618
17 1 4 0 1 0 820
17 1 4 0 2 0
17 1 4 1 1 1.45825108 543
17 1 4 1 2 1.120815851
17 1 4 2 1 1.64691522 642
17 1 4 2 2 1.348012151
17 1 4 3 1 0.241927258 687
17 1 4 3 2 0.900080731
17 2 1 0 1 0 221
17 2 1 0 2 0
17 2 1 1 1 -1.613478217 862
17 2 1 1 2 4.465728837
17 2 1 2 1 -0.572767577 889
17 2 1 2 2 5.224925152
17 2 1 3 1 -1.25141956 745
17 2 1 3 2 2.06509017
17 2 2 0 1 0 221
17 2 2 0 2 0
17 2 2 1 1 -0.147523949 240
17 2 2 1 2 5.458730188
17 2 2 2 1 0.087275339 1265
17 2 2 2 2 -2.042732631
17 2 2 3 1 1.598957158 847
17 2 2 3 2 2.882881538
17 2 3 0 1 0 221
17 2 3 0 2 0
17 2 3 1 1 0.005181264 969
17 2 3 1 2 -6.775280094
17 2 3 2 1 3.489068427 1180
Appendices
136
17 2 3 2 2 11.33134177
17 2 3 3 1 -1.304664362 365
17 2 3 3 2 3.931301735
17 2 4 0 1 0 221
17 2 4 0 2 0
17 2 4 1 1 -0.769318801 280
17 2 4 1 2 -2.565514403
17 2 4 2 1 0.353439387 560
17 2 4 2 2 3.494097053
17 2 4 3 1 -0.572767577 766
17 2 4 3 2 -2.565514403
18 1 1 0 1 0.359 0 1060
18 1 1 0 2 1.0575 0
18 1 1 1 1 0.3725 -5.678425312 2214
18 1 1 1 2 1.0275 -1.30225725
18 1 1 2 1 0.2635 -0.258564116 2563
18 1 1 2 2 1.019 0.079581444
18 1 1 3 1 0.351 -8.488759227 3211
18 1 1 3 2 1.0845 -8.404252448
18 1 2 0 1 0.359 0 1060
18 1 2 0 2 1.0575 0
18 1 2 1 1 0.4465 0.743797164 3580
18 1 2 1 2 1.0655 1.590006601
18 1 2 2 1 1.836 -0.39634065 4019
18 1 2 2 2 1.706 -0.081060974
18 1 2 3 1 0.4295 -1.039331134 5760
18 1 2 3 2 1.055 0.812001748
18 1 3 0 1 0.359 0 1060
18 1 3 0 2 1.0575 0
18 1 3 1 1 0.41 -0.5051648 2080
Appendices
137
18 1 3 1 2 0.9675 -1.053636839
18 1 3 2 1 0.413 2.372360624 1480
18 1 3 2 2 1.007 -1.135273099
18 1 3 3 1 0.3855 0.16413165 3324
18 1 3 3 2 1.0545 1.741952632
18 1 4 0 1 0.359 0 1060
18 1 4 0 2 1.0575 0
18 1 4 1 1 0.3425 -0.150254862 3930
18 1 4 1 2 1.099 -2.900923934
18 1 4 2 1 0.3465 0.665688726 1784
18 1 4 2 2 1.012 -0.393216619
18 1 4 3 1 0.3795 -0.858892914 1740
18 1 4 3 2 1.076 -1.805814379
18 2 1 0 1 0.979 0 1340
18 2 1 0 2 1.053 0
18 2 1 1 1 0.915 -8.543354782 1543
18 2 1 1 2 0.9295 -1.543170149
18 2 1 2 1 0.9825 -10.90809664 1680
18 2 1 2 2 0.9685 -1.798537614
18 2 1 3 1 0.905 -7.787017238 780
18 2 1 3 2 1.008 -3.87237691
18 2 2 0 1 0.979 0 1340
18 2 2 0 2 1.053 0
18 2 2 1 1 1.1065 -2.350874482 622
18 2 2 1 2 1.0305 1.495958428
18 2 2 2 1 1.75 -0.917848921 2765
18 2 2 2 2 1.85 -2.186974475
18 2 2 3 1 1.062 -5.554366022 2189
18 2 2 3 2 1.043 1.156304391
18 2 3 0 1 0.979 0 1340
Appendices
138
18 2 3 0 2 1.053 0
18 2 3 1 1 0.815 -2.975061806 1860
18 2 3 1 2 0.969 3.920367441
18 2 3 2 1 0.9955 -6.623751312 2720
18 2 3 2 2 0.938 1.672629549
18 2 3 3 1 1.0005 -15.29945635 860
18 2 3 3 2 1.0025 1.102683033
18 2 4 0 1 0.979 0 1340
18 2 4 0 2 1.053 0
18 2 4 1 1 0.9735 -4.908160097 1660
18 2 4 1 2 1.074 0.458663601
18 2 4 2 1 0.876 -1.591640315 1567
18 2 4 2 2 0.9785 1.401697593
18 2 4 3 1 0.9365 -18.35720977 4711
18 2 4 3 2 1.026 1.933761632
19 1 1 0 1 0.397 0 1040
19 1 1 0 2 0.805 0
19 1 1 1 1 0.4365 3.097164815 460
19 1 1 1 2 0.8265 0.93370896
19 1 1 2 1 0.325 3.640476128 1520
19 1 1 2 2 0.875 -0.810964256
19 1 1 3 1 0.353 3.619338456 280
19 1 1 3 2 1.0755 -2.449518701
19 1 2 0 1 0.397 0 1040
19 1 2 0 2 0.805 0
19 1 2 1 1 0.3045 -0.250103623 941
19 1 2 1 2 1.1105 -4.101669552
19 1 2 2 1 0.3765 0.806551058 668
19 1 2 2 2 0.9865 -11.2472093
19 1 2 3 1 0.3425 4.755304575 1763
Appendices
139
19 1 2 3 2 0.935 -0.879320347
19 1 3 0 1 0.397 0 1040
19 1 3 0 2 0.805 0
19 1 3 1 1 0.3325 2.613154326 1220
19 1 3 1 2 0.976 -2.951383267
19 1 3 2 1 0.232 8.735984991 780
19 1 3 2 2 0.9625 5.562666988
19 1 3 3 1 0.286 1.209067903 415
19 1 3 3 2 1.078 -1.808362413
19 1 4 0 1 0.397 0 1040
19 1 4 0 2 0.805 0
19 1 4 1 1 0.2205 -4.101705482 462
19 1 4 1 2 1.0495 -0.896507968
19 1 4 2 1 0.382 1.403480894 743
19 1 4 2 2 1.111 -12.56598088
19 1 4 3 1 0.426 1.11016977 1160
19 1 4 3 2 1.2185 -8.576469663
19 2 1 0 1 0.809 0 805
19 2 1 0 2 0.8575 0
19 2 1 1 1 0.763 4.994322812 380
19 2 1 1 2 0.8645 2.943969437
19 2 1 2 1 0.7515 2.251073924 304
19 2 1 2 2 0.709 5.894393683
19 2 1 3 1 0.799 3.519243889 187
19 2 1 3 2 0.9755 -4.084477702
19 2 2 0 1 0.809 0 805
19 2 2 0 2 0.8575 0
19 2 2 1 1 0.7945 1.750939748 342
19 2 2 1 2 0.958 3.266577527
19 2 2 2 1 0.741 4.47743181 200
Appendices
140
19 2 2 2 2 0.7715 5.243806492
19 2 2 3 1 0.685 2.754244989 449
19 2 2 3 2 0.729 8.665582057
19 2 3 0 1 0.809 0 805
19 2 3 0 2 0.8575 0
19 2 3 1 1 0.713 4.929207947 3324
19 2 3 1 2 0.755 5.052734095
19 2 3 2 1 0.9075 10.23213835 560
19 2 3 2 2 0.695 12.86962171
19 2 3 3 1 0.741 4.7820698 544
19 2 3 3 2 0.824 -1.427341518
19 2 4 0 1 0.809 0 805
19 2 4 0 2 0.8575 0
19 2 4 1 1 0.9245 -2.653476572 588
19 2 4 1 2 0.886 -4.355423924
19 2 4 2 1 0.5575 3.411753312 226
19 2 4 2 2 0.8115 1.104441004
19 2 4 3 1 0.4975 -0.395210554 307
19 2 4 3 2 1.0045 0.594297528
20 1 1 0 1 1.053 0 302
20 1 1 0 2 0.701 0
20 1 1 1 1 0.9295 -9.019663532 687
20 1 1 1 2 1.0095 -20.31733492
20 1 1 2 1 0.9685 -4.402956598 860
20 1 1 2 2 0.931 -1.443782299
20 1 1 3 1 1.008 -6.278043753 1786
20 1 1 3 2 0.829 -1.055922065
20 1 2 0 1 1.053 0 302
20 1 2 0 2 0.701 0
20 1 2 1 1 1.0305 -0.816633793 568
Appendices
141
20 1 2 1 2 0.9285 -4.697431709
20 1 2 2 1 1.85 0.522861137 1180
20 1 2 2 2 2.0965 5.85382866
20 1 2 3 1 1.043 0.169502543 1084
20 1 2 3 2 0.9605 5.442327376
20 1 3 0 1 1.053 0 302
20 1 3 0 2 0.701 0
20 1 3 1 1 0.969 0.89520906 920
20 1 3 1 2 0.88 -12.4183493
20 1 3 2 1 0.938 0.147647223 1389
20 1 3 2 2 0.9345 2.918240855
20 1 3 3 1 1.0025 2.341578495 544
20 1 3 3 2 0.759 1.604311018
20 1 4 0 1 1.053 0 302
20 1 4 0 2 0.701 0
20 1 4 1 1 1.074 1.09123811 760
20 1 4 1 2 1.0705 2.332845954
20 1 4 2 1 0.9785 2.190980068 1268
20 1 4 2 2 0.8425 1.200951475
20 1 4 3 1 1.026 0.383953769 543
20 1 4 3 2 0.792 -4.250325449
20 2 1 0 1 1.463 0 346
20 2 1 0 2 0.826 0
20 2 1 1 1 1.634 3.372677405 1440
20 2 1 1 2 0.811 -7.766697965
20 2 1 2 1 1.61 3.418389898 743
20 2 1 2 2 0.8155 0.600379994
20 2 1 3 1 1.438 -3.696628442 1342
20 2 1 3 2 0.9115 -5.77402072
20 2 2 0 1 1.463 0 346
Appendices
142
20 2 2 0 2 0.826 0
20 2 2 1 1 1.886 1.864982133 403
20 2 2 1 2 0.707 2.729480532
20 2 2 2 1 2.384 1.42940181 106
20 2 2 2 2 1.4205 2.126295311
20 2 2 3 1 1.8305 4.336247056 546
20 2 2 3 2 0.671 0.637058049
20 2 3 0 1 1.463 0 346
20 2 3 0 2 0.826 0
20 2 3 1 1 1.7195 3.165748844 1943
20 2 3 1 2 0.7325 -0.577961583
20 2 3 2 1 1.2405 4.636777501 1461
20 2 3 2 2 0.931 1.507597718
20 2 3 3 1 1.735 1.287394135 247
20 2 3 3 2 0.7365 -1.28905427
20 2 4 0 1 1.463 0 346
20 2 4 0 2 0.826 0
20 2 4 1 1 2.007 -1.439754903 1360
20 2 4 1 2 0.7785 0.299229167
20 2 4 2 1 1.7615 -1.709292891 246
20 2 4 2 2 0.8415 0.329972155
20 2 4 3 1 1.4505 2.109510099 288
20 2 4 3 2 0.804 2.528671122
21 1 1 0 1 0.961 0 1042
21 1 1 0 2 0.323 0
21 1 1 1 1 1.0065 1.621050621 660
21 1 1 1 2 0.8035 0.089369246
21 1 1 2 1 1.2725 0.813243145 988
21 1 1 2 2 0.8825 2.510649962
21 1 1 3 1 1.235 -2.136152147 342
Appendices
143
21 1 1 3 2 1.064 2.909496208
21 1 2 0 1 0.961 0 1042
21 1 2 0 2 0.323 0
21 1 2 1 1 1.006 -0.803321104 706
21 1 2 1 2 0.8365 -0.358539312
21 1 2 2 1 1.0375 1.24788532 360
21 1 2 2 2 1.04 3.775474937
21 1 2 3 1 1.012 -7.437804983 581
21 1 2 3 2 0.7075 1.802464312
21 1 3 0 1 0.961 0 1042
21 1 3 0 2 0.323 0
21 1 3 1 1 1.4705 -1.597422106 944
21 1 3 1 2 1.2255 -1.633324361
21 1 3 2 1 1.03 5.05345191 682
21 1 3 2 2 0.8195 6.793373016
21 1 3 3 1 0.994 -0.448920645 524
21 1 3 3 2 0.889 -1.482379466
21 1 4 0 1 0.961 0 1042
21 1 4 0 2 0.323 0
21 1 4 1 1 1.031 -11.47144172 460
21 1 4 1 2 0.722 1.123845226
21 1 4 2 1 1.0455 -5.374585502 349
21 1 4 2 2 0.956 -2.712334337
21 1 4 3 1 1.091 -7.11520409 704
21 1 4 3 2 0.7965 -7.914433523
21 2 1 0 1 1.071 0 346
21 2 1 0 2 0.891 0
21 2 1 1 1 1.213 -13.10305073 1480
21 2 1 1 2 0.823 -9.794160849
21 2 1 2 1 1.0325 -3.313618536 1124
Appendices
144
21 2 1 2 2 0.7675 4.695137876
21 2 1 3 1 1.085 -2.603003806 622
21 2 1 3 2 0.5735 6.312856327
21 2 2 0 1 1.071 0 346
21 2 2 0 2 0.891 0
21 2 2 1 1 1.213 0.197826314 480
21 2 2 1 2 0.9325 4.477922436
21 2 2 2 1 1.024 -0.536321885 563
21 2 2 2 2 0.873 7.213493148
21 2 2 3 1 1.212 -2.181162219 831
21 2 2 3 2 0.695 3.034755778
21 2 3 0 1 1.071 0 346
21 2 3 0 2 0.891 0
21 2 3 1 1 1.3245 -0.750941916 249
21 2 3 1 2 0.7065 -0.0139777
21 2 3 2 1 1.229 3.381504769 423
21 2 3 2 2 0.7025 11.11997712
21 2 3 3 1 1.1755 -0.852658448 905
21 2 3 3 2 0.56 3.583221376
21 2 4 0 1 1.071 0 346
21 2 4 0 2 0.891 0
21 2 4 1 1 1.204 -12.56747987 722
21 2 4 1 2 1.018 -2.320509203
21 2 4 2 1 1.1155 -5.012642146 321
21 2 4 2 2 0.9505 7.902333407
21 2 4 3 1 1.1695 -1.651027359 1347
21 2 4 3 2 0.646 4.805643173
22 1 1 0 1 1.121 0 1520
22 1 1 0 2 1.114 0
22 1 1 1 1 0.836 -2.582351261 900
Appendices
145
22 1 1 1 2 1.1885 2.976027278
22 1 1 2 1 1.085 0.146515341 1300
22 1 1 2 2 1.096 3.296421595
22 1 1 3 1 1.0915 -2.901593232 800
22 1 1 3 2 1.088 -3.302016474
22 1 2 0 1 1.121 0 1520
22 1 2 0 2 1.114 0
22 1 2 1 1 0.8605 -3.319772529 440
22 1 2 1 2 1.193 4.345553258
22 1 2 2 1 1.681 -42.67840665 720
22 1 2 2 2 1.7055 4.865101728
22 1 2 3 1 0.832 4.948061054 780
22 1 2 3 2 0.9965 4.659510811
22 1 3 0 1 1.121 0 1520
22 1 3 0 2 1.114 0
22 1 3 1 1 0.937 1.021823164 840
22 1 3 1 2 0.956 5.259946337
22 1 3 2 1 0.8935 3.339004446 1060
22 1 3 2 2 1.082 4.268394879
22 1 3 3 1 0.9925 4.740082154 1100
22 1 3 3 2 1.06 5.186742752
22 1 4 0 1 1.121 0 1520
22 1 4 0 2 1.114 0
22 1 4 1 1 0.8015 -1.513478002 500
22 1 4 1 2 1.201 -0.630157247
22 1 4 2 1 0.94 -3.657930776 1860
22 1 4 2 2 1.118 4.790402102
22 1 4 3 1 0.996 -2.799137819 1220
22 1 4 3 2 1.1155 -26.80365701
22 2 1 0 1 1.1515 0 1160
Appendices
146
22 2 1 0 2 0.861 0
22 2 1 1 1 1.0535 0.290447908 480
22 2 1 1 2 0.837 0.290447908
22 2 1 2 1 1.1395 1.171377247 520
22 2 1 2 2 0.5815 1.171377247
22 2 1 3 1 1.139 0.290447908 780
22 2 1 3 2 0.449 -7.671079378
22 2 2 0 1 1.1515 0 1160
22 2 2 0 2 0.861 0
22 2 2 1 1 1.091 2.225831335 860
22 2 2 1 2 0.841 2.225831335
22 2 2 2 1 1.7145 0.229236654 1160
22 2 2 2 2 1.487 -0.582137344
22 2 2 3 1 1.2325 -0.543067848 820
22 2 2 3 2 0.6725 -0.543067848
22 2 3 0 1 1.1515 0 1160
22 2 3 0 2 0.861 0
22 2 3 1 1 0.9305 -0.345452607 680
22 2 3 1 2 0.7505 -0.345452607
22 2 3 2 1 1.182 -0.582137344 620
22 2 3 2 2 0.646 0.229236654
22 2 3 3 1 1.1255 -1.122533767 500
22 2 3 3 2 0.6085 -1.122533767
22 2 4 0 1 1.1515 0 1160
22 2 4 0 2 0.861 0
22 2 4 1 1 0.838 1.693143653 1140
22 2 4 1 2 0.778 1.693143653
22 2 4 2 1 1.0275 0.788042606 1100
22 2 4 2 2 0.7525 0.788042606
22 2 4 3 1 1.148 1.343578688 900
Appendices
147
22 2 4 3 2 0.6455 1.343578688
23 1 1 0 1 1.3145 0 880
23 1 1 0 2 1.2705 0
23 1 1 1 1 1.249 2.968532717 360
23 1 1 1 2 1.177 2.830370063
23 1 1 2 1 1.249 5.440333624 320
23 1 1 2 2 1.1885 3.873461203
23 1 1 3 1 1.323 6.594801788 840
23 1 1 3 2 1.3225 6.846937883
23 1 2 0 1 1.3145 0 880
23 1 2 0 2 1.2705 0
23 1 2 1 1 1.2025 6.129071796 1140
23 1 2 1 2 1.2835 4.63871579
23 1 2 2 1 0.924 5.786392021 900
23 1 2 2 2 1.2535 5.600908572
23 1 2 3 1 0.9005 3.673917705 980
23 1 2 3 2 1.187 6.057017546
23 1 3 0 1 1.3145 0 880
23 1 3 0 2 1.2705 0
23 1 3 1 1 1.1255 6.158072351 360
23 1 3 1 2 1.244 4.461128962
23 1 3 2 1 1.33 10.16758686 660
23 1 3 2 2 1.292 9.963501517
23 1 3 3 1 1.049 6.750516101 1160
23 1 3 3 2 1.251 6.99175518
23 1 4 0 1 1.3145 0 880
23 1 4 0 2 1.2705 0
23 1 4 1 1 1.2385 4.490360045 880
23 1 4 1 2 1.3065 6.073982675
23 1 4 2 1 1.2685 4.582165903 520
Appendices
148
23 1 4 2 2 1.3 6.326909141
23 1 4 3 1 1.0845 4.987087495 440
23 1 4 3 2 1.3085 6.691927699
23 2 1 0 1 1.366 0 840
23 2 1 0 2 0.795 0
23 2 1 1 1 1.2725 3.248226166 920
23 2 1 1 2 0.71 0.728355635
23 2 1 2 1 1.284 3.921367635 640
23 2 1 2 2 0.656 1.505353257
23 2 1 3 1 1.418 0.728355635 880
23 2 1 3 2 0.6725 1.74948928
23 2 2 0 1 1.366 0 840
23 2 2 0 2 0.795 0
23 2 2 1 1 1.379 3.716636071 1800
23 2 2 1 2 1.0435 1.384005119
23 2 2 2 1 1.349 4.591761443 1340
23 2 2 2 2 0.841 1.31605379
23 2 2 3 1 1.2825 5.895779931 1120
23 2 2 3 2 0.5505 1.279688413
23 2 3 0 1 1.366 0 840
23 2 3 0 2 0.795 0
23 2 3 1 1 1.3395 4.977370408 460
23 2 3 1 2 0.5635 1.912662691
23 2 3 2 1 1.3875 6.847490526 540
23 2 3 2 2 0.5905 3.442651098
23 2 3 3 1 1.3465 6.180663986 480
23 2 3 3 2 0.6945 2.515676606
23 2 4 0 1 1.366 0 840
23 2 4 0 2 0.795 0
23 2 4 1 1 1.402 3.903181263 1040
Appendices
149
23 2 4 1 2 0.588 -0.882930252
23 2 4 2 1 1.3955 3.834231568 1100
23 2 4 2 2 0.651 0.46631346
23 2 4 3 1 1.404 1.404859621 640
23 2 4 3 2 0.6335 0.447895308
24 1 1 0 1 0.878 0 440
24 1 1 0 2 0.4535 0
24 1 1 1 1 1.038 -8.918214248 900
24 1 1 1 2 0.348 1.235557017
24 1 1 2 1 0.854 -0.9175263 340
24 1 1 2 2 0.5035 0.525322754
24 1 1 3 1 0.879 -7.12801153 640
24 1 1 3 2 0.452 -6.647930059
24 1 2 0 1 0.878 0 440
24 1 2 0 2 0.4535 0
24 1 2 1 1 1.016 -4.479417984 700
24 1 2 1 2 0.351 0.180374548
24 1 2 2 1 1.5345 1.179814074 860
24 1 2 2 2 0.679 1.346659888
24 1 2 3 1 0.832 -1.768196116 760
24 1 2 3 2 0.3515 1.826036137
24 1 3 0 1 0.878 0 440
24 1 3 0 2 0.4535 0
24 1 3 1 1 0.79 -1.418671882 1340
24 1 3 1 2 0.299 0.677696712
24 1 3 2 1 0.801 -1.574698234 1080
24 1 3 2 2 0.218 2.808956909
24 1 3 3 1 0.8595 -3.013302629 920
24 1 3 3 2 0.2675 3.477089707
24 1 4 0 1 0.878 0 440
Appendices
150
24 1 4 0 2 0.4535 0
24 1 4 1 1 0.8785 -8.199287231 880
24 1 4 1 2 0.2805 0.627372473
24 1 4 2 1 0.8195 0.537200583 760
24 1 4 2 2 0.054 1.830972826
24 1 4 3 1 0.8725 -4.294783926 600
24 1 4 3 2 0.31 3.029718384
24 2 1 0 1 1.0895 0 1480
24 2 1 0 2 0.2335 0
24 2 1 1 1 1.0985 -6.542361529 360
24 2 1 1 2 0.311 -0.399329395
24 2 1 2 1 0.9445 -1.254391438 480
24 2 1 2 2 0.241 7.094677598
24 2 1 3 1 0.989 -0.399329395 340
24 2 1 3 2 0.1025 18.56846916
24 2 2 0 1 1.0895 0 1480
24 2 2 0 2 0.2335 0
24 2 2 1 1 1.1415 0.967562454 740
24 2 2 1 2 0.157 17.92065789
24 2 2 2 1 1.6685 -2.339911403 520
24 2 2 2 2 0.8805 9.780240807
24 2 2 3 1 1.023 -3.475932412 420
24 2 2 3 2 0.271 13.79405222
24 2 3 0 1 1.0895 0 1480
24 2 3 0 2 0.2335 0
24 2 3 1 1 1.114 2.270540089 1160
24 2 3 1 2 0.1925 16.99448008
24 2 3 2 1 1.1285 4.667188004 600
24 2 3 2 2 0.1295 16.79501339
24 2 3 3 1 0.9845 -4.225303229 700
Appendices
151
24 2 3 3 2 0.303 17.82768896
24 2 4 0 1 1.0895 0 1480
24 2 4 0 2 0.2335 0
24 2 4 1 1 0.978 2.076127098 1000
24 2 4 1 2 0.164 13.7536211
24 2 4 2 1 0.9745 -11.53948539 380
24 2 4 2 2 0.134 18.8446528
24 2 4 3 1 1.0165 -7.475603531 300
24 2 4 3 2 0.436 13.79405222
25 1 1 0 1 0.9435 0 2020
25 1 1 0 2 0.6315 0
25 1 1 1 1 0.9795 -5.429470811 1460
25 1 1 1 2 0.878 0.878179501
25 1 1 2 1 0.9675 -3.695136044 1400
25 1 1 2 2 0.6135 1.677009779
25 1 1 3 1 0.922 -0.196352656 1540
25 1 1 3 2 0.778 0.353341274
25 1 2 0 1 0.9435 0 2020
25 1 2 0 2 0.6315 0
25 1 2 1 1 1.0215 -2.01218968 620
25 1 2 1 2 0.5005 -0.337484546
25 1 2 2 1 0.996 -0.348181352 1120
25 1 2 2 2 0.454 1.610935513
25 1 2 3 1 0.971 -0.039561907 1420
25 1 2 3 2 0.534 0.216039478
25 1 3 0 1 0.9435 0 2020
25 1 3 0 2 0.6315 0
25 1 3 1 1 0.986 -1.961719493 840
25 1 3 1 2 0.733 0.018860672
25 1 3 2 1 0.851 3.261717476 1820
Appendices
152
25 1 3 2 2 0.631 4.456248243
25 1 3 3 1 0.86 0.499906952 1120
25 1 3 3 2 0.7585 0.515657721
25 1 4 0 1 0.9435 0 2020
25 1 4 0 2 0.6315 0
25 1 4 1 1 0.872 -2.151248312 520
25 1 4 1 2 0.59 1.818418356
25 1 4 2 1 0.8745 -0.736243475 1040
25 1 4 2 2 0.577 2.501912885
25 1 4 3 1 0.8205 -1.538705462 1680
25 1 4 3 2 0.613 1.525586608
25 2 1 0 1 1.017 0 640
25 2 1 0 2 0.4405 0
25 2 1 1 1 1.148 -2.355697168 500
25 2 1 1 2 0.457 -0.51205951
25 2 1 2 1 1.109 0.814880721 520
25 2 1 2 2 0.5045 0.849472632
25 2 1 3 1 1.167 -0.51205951 740
25 2 1 3 2 0.295 2.125482671
25 2 2 0 1 1.017 0 640
25 2 2 0 2 0.4405 0
25 2 2 1 1 1.1755 -8.19226813 680
25 2 2 1 2 0.283 -5.722382274
25 2 2 2 1 1.169 -16.11655866 380
25 2 2 2 2 0.2815 -1.112587313
25 2 2 3 1 1.21 0.454144825 520
25 2 2 3 2 0.3725 1.590297682
25 2 3 0 1 1.017 0 640
25 2 3 0 2 0.4405 0
25 2 3 1 1 1.122 -10.049754 600
Appendices
153
25 2 3 1 2 0.1945 -2.237631495
25 2 3 2 1 0.959 6.016811813 1380
25 2 3 2 2 0.412 13.0789766
25 2 3 3 1 0.9755 -8.404041034 700
25 2 3 3 2 0.278 1.225215454
25 2 4 0 1 1.017 0 640
25 2 4 0 2 0.4405 0
25 2 4 1 1 0.999 -8.636787502 660
25 2 4 1 2 0.234 -11.55195238
25 2 4 2 1 0.993 -1.851056564 720
25 2 4 2 2 0.303 -2.162599573
25 2 4 3 1 1.012 -1.789914823 700
25 2 4 3 2 0.261 -16.14141772
26 1 1 0 1 0.9055 0 540
26 1 1 0 2 1.111 0
26 1 1 1 1 0.823 2.124350558 500
26 1 1 1 2 0.8385 1.74767498
26 1 1 2 1 0.6675 2.566822832 660
26 1 1 2 2 0.812 1.515989417
26 1 1 3 1 0.3735 -8.419285846 700
26 1 1 3 2 1.0045 -8.214507487
26 1 2 0 1 0.9055 0 540
26 1 2 0 2 1.111 0
26 1 2 1 1 0.8595 1.962782772 800
26 1 2 1 2 1.651 1.30274818
26 1 2 2 1 1.634 1.186463193 1200
26 1 2 2 2 0.848 1.480858613
26 1 2 3 1 0.7715 1.226212658 820
26 1 2 3 2 0.764 -0.644096134
26 1 3 0 1 0.9055 0 540
Appendices
154
26 1 3 0 2 1.111 0
26 1 3 1 1 -0.168 0.441190417 860
26 1 3 1 2 0.9045 0.395560089
26 1 3 2 1 0.3945 2.172401063 520
26 1 3 2 2 0.917 1.737979771
26 1 3 3 1 0.8105 0.128137207 280
26 1 3 3 2 0.8165 0.919100054
26 1 4 0 1 0.9055 0 540
26 1 4 0 2 1.111 0
26 1 4 1 1 0.437 2.428641179 1020
26 1 4 1 2 0.7585 -0.021001295
26 1 4 2 1 1.219 2.780153922 320
26 1 4 2 2 0.8205 1.639163483
26 1 4 3 1 0.565 0.676505297 360
26 1 4 3 2 0.657 1.009907191
26 2 1 0 1 0.903 0 960
26 2 1 0 2 0.5595 0
26 2 1 1 1 0.746 10.11075877 540
26 2 1 1 2 0.6005 0.439973189
26 2 1 2 1 1.0755 3.397976814 680
26 2 1 2 2 0.554 2.099282132
26 2 1 3 1 0.899 12.58689822 420
26 2 1 3 2 0.807 -7.641675385
26 2 2 0 1 0.903 0 960
26 2 2 0 2 0.5595 0
26 2 2 1 1 0.9245 10.00511648 400
26 2 2 1 2 0.5975 2.085326611
26 2 2 2 1 1.699 -4.19480258 660
26 2 2 2 2 1.4805 1.871839729
26 2 2 3 1 0.943 -16.43175036 640
Appendices
155
26 2 2 3 2 0.585 -0.868296683
26 2 3 0 1 0.903 0 960
26 2 3 0 2 0.5595 0
26 2 3 1 1 0.9405 16.62157262 720
26 2 3 1 2 0.7705 0.023536727
26 2 3 2 1 0.905 13.47993929 300
26 2 3 2 2 0.7055 1.155367413
26 2 3 3 1 0.674 -2.509925381 1000
26 2 3 3 2 0.685 0.861825867
26 2 4 0 1 0.903 0 960
26 2 4 0 2 0.5595 0
26 2 4 1 1 0.8445 19.8495471 280
26 2 4 1 2 0.606 0.551830806
26 2 4 2 1 0.789 14.85586202 960
26 2 4 2 2 0.5235 2.712807274
26 2 4 3 1 0.7855 -13.37447819 780
26 2 4 3 2 0.552 -0.43632987
27 1 1 0 1 1.7365 0 1120
27 1 1 0 2 1.0005 0
27 1 1 1 1 1.563 -1.178011087 680
27 1 1 1 2 0.6745 0.937122957
27 1 1 2 1 1.439 0.446742185 600
27 1 1 2 2 0.568 -2.49730135
27 1 1 3 1 1.422 -0.741675775 480
27 1 1 3 2 0.6345 -0.123261808
27 1 2 0 1 1.7365 0 1120
27 1 2 0 2 1.0005 0
27 1 2 1 1 1.2595 0.538888356 300
27 1 2 1 2 0.7365 -0.333973852
27 1 2 2 1 1.205 0.102684271 920
Appendices
156
27 1 2 2 2 0.5985 1.741480919
27 1 2 3 1 0.8405 -2.437319724 960
27 1 2 3 2 0.643 0.734198635
27 1 3 0 1 1.7365 0 1120
27 1 3 0 2 1.0005 0
27 1 3 1 1 1.522 0.419585898 440
27 1 3 1 2 0.7215 1.62386965
27 1 3 2 1 1.0945 1.384921533 400
27 1 3 2 2 0.6095 2.493607354
27 1 3 3 1 1.402 -0.593431718 980
27 1 3 3 2 0.636 0.940080531
27 1 4 0 1 1.7365 0 1120
27 1 4 0 2 1.0005 0
27 1 4 1 1 1.393 0.823036896 1080
27 1 4 1 2 0.5975 -0.637247101
27 1 4 2 1 1.1625 -0.475254675 860
27 1 4 2 2 0.583 -0.768110122
27 1 4 3 1 1.257 -0.396927809 740
27 1 4 3 2 0.657 -2.115894512
27 2 1 0 1 0.7795 0 1040
27 2 1 0 2 0.4805 0
27 2 1 1 1 0.5785 11.77281649 520
27 2 1 1 2 0.5635 -2.462988478
27 2 1 2 1 0.754 3.294361104 880
27 2 1 2 2 0.446 -2.288328928
27 2 1 3 1 0.5665 -0.220384043 680
27 2 1 3 2 0.3795 -11.03510687
27 2 2 0 1 0.7795 0 1040
27 2 2 0 2 0.4805 0
27 2 2 1 1 0.7745 14.76924948 640
Appendices
157
27 2 2 1 2 0.559 -1.380476381
27 2 2 2 1 0.773 -10.82971424 720
27 2 2 2 2 0.4925 -2.253210513
27 2 2 3 1 0.6 6.72147081 420
27 2 2 3 2 0.366 -2.04834102
27 2 3 0 1 0.7795 0 1040
27 2 3 0 2 0.4805 0
27 2 3 1 1 0.787 15.26401708 840
27 2 3 1 2 0.5115 -3.828724218
27 2 3 2 1 0.7345 20.14532547 1140
27 2 3 2 2 0.466 1.072980738
27 2 3 3 1 0.5595 -4.872311461 1040
27 2 3 3 2 0.43 -7.70800773
27 2 4 0 1 0.7795 0 1040
27 2 4 0 2 0.4805 0
27 2 4 1 1 0.6525 14.60533399 880
27 2 4 1 2 0.566 -2.959720852
27 2 4 2 1 0.745 2.452415449 580
27 2 4 2 2 0.4415 -3.364406833
27 2 4 3 1 0.557 1.114516579 660
27 2 4 3 2 0.544 -8.372344781
28 1 1 0 1 0 400
28 1 1 0 2 0
28 1 1 1 1 -3.523779469 700
28 1 1 1 2 5.847486212
28 1 1 2 1 -5.688794304 320
28 1 1 2 2 1.245622267
28 1 1 3 1 -6.527039733 260
28 1 1 3 2 2.688156307
28 1 2 0 1 0 400
Appendices
158
28 1 2 0 2 0
28 1 2 1 1 -2.412330833 280
28 1 2 1 2 7.627262345
28 1 2 2 1 -2.137944466 520
28 1 2 2 2 6.011935633
28 1 2 3 1 -2.412330833 960
28 1 2 3 2 8.738255866
28 1 3 0 1 0 400
28 1 3 0 2 0
28 1 3 1 1 -3.257761637 820
28 1 3 1 2 8.141153561
28 1 3 2 1 -1.24434665 720
28 1 3 2 2 8.494294848
28 1 3 3 1 -5.743842877 760
28 1 3 3 2 8.973663443
28 1 4 0 1 0 400
28 1 4 0 2 0
28 1 4 1 1 -1.015356426 400
28 1 4 1 2 2.540351659
28 1 4 2 1 -1.909694485 680
28 1 4 2 2 5.172381414
28 1 4 3 1 -2.004032795 940
28 1 4 3 2 6.076924326
28 2 1 0 1 0 340
28 2 1 0 2 0
28 2 1 1 1 4.572629864 720
28 2 1 1 2 5.340097818
28 2 1 2 1 4.9126723 700
28 2 1 2 2 12.70519257
28 2 1 3 1 6.476004519 580
Appendices
159
28 2 1 3 2 8.932895471
28 2 2 0 1 0 340
28 2 2 0 2 0
28 2 2 1 1 9.642593975 660
28 2 2 1 2 4.035001628
28 2 2 2 1 8.239460516 560
28 2 2 2 2 -8.366231138
28 2 2 3 1 7.136123872 460
28 2 2 3 2 -2.415088674
28 2 3 0 1 0 340
28 2 3 0 2 0
28 2 3 1 1 7.30767386 540
28 2 3 1 2 -2.179486038
28 2 3 2 1 12.168656 400
28 2 3 2 2 19.42698797
28 2 3 3 1 8.059854683 680
28 2 3 3 2 -2.283896993
28 2 4 0 1 0 340
28 2 4 0 2 0
28 2 4 1 1 0.737421268 420
28 2 4 1 2 -2.049646698
28 2 4 2 1 6.583235043 320
28 2 4 2 2 6.396602524
28 2 4 3 1 5.570545996 620
28 2 4 3 2 -3.54742983
29 1 1 0 1 0 380
29 1 1 0 2 0
29 1 1 1 1 2.357367294 560
29 1 1 1 2 0.476506268
29 1 1 2 1 3.08000318 240
Appendices
160
29 1 1 2 2 1.09838334
29 1 1 3 1 -0.297511614 520
29 1 1 3 2 1.061820922
29 1 2 0 1 0 380
29 1 2 0 2 0
29 1 2 1 1 1.71531238 340
29 1 2 1 2 -2.145528383
29 1 2 2 1 2.191035316 760
29 1 2 2 2 1.81504882
29 1 2 3 1 1.36219159 720
29 1 2 3 2 1.087966985
29 1 3 0 1 0 380
29 1 3 0 2 0
29 1 3 1 1 1.112856123 660
29 1 3 1 2 0.506011993
29 1 3 2 1 5.638820176 420
29 1 3 2 2 4.603031398
29 1 3 3 1 2.789061791 500
29 1 3 3 2 0.819608297
29 1 4 0 1 0 380
29 1 4 0 2 0
29 1 4 1 1 -0.069291529 760
29 1 4 1 2 -0.974796169
29 1 4 2 1 -2.435931429 740
29 1 4 2 2 0.051496441
29 1 4 3 1 1.524117722 200
29 1 4 3 2 0.301982788
29 2 1 0 1 0 520
29 2 1 0 2 0
29 2 1 1 1 -0.014176113 660
Appendices
161
29 2 1 1 2 2.599308826
29 2 1 2 1 0.653821791 520
29 2 1 2 2 3.487744939
29 2 1 3 1 -8.66706699 460
29 2 1 3 2 -3.633773735
29 2 2 0 1 0 520
29 2 2 0 2 0
29 2 2 1 1 0.088653922 440
29 2 2 1 2 3.894609987
29 2 2 2 1 0.716672736 580
29 2 2 2 2 3.077205605
29 2 2 3 1 0.508101752 300
29 2 2 3 2 3.435532112
29 2 3 0 1 0 520
29 2 3 0 2 0
29 2 3 1 1 0.394779044 540
29 2 3 1 2 5.402407504
29 2 3 2 1 0.014127235 680
29 2 3 2 2 4.795505569
29 2 3 3 1 -0.722156878 600
29 2 3 3 2 3.924664265
29 2 4 0 1 0 520
29 2 4 0 2 0
29 2 4 1 1 1.500153357 720
29 2 4 1 2 2.857257393
29 2 4 2 1 -0.129365045 620
29 2 4 2 2 3.815654358
29 2 4 3 1 -1.617465269 260
29 2 4 3 2 3.235394582
30 1 1 0 1 1.1785 0 800
Appendices
162
30 1 1 0 2 1.1605 0
30 1 1 1 1 0.778 3.005786546 500
30 1 1 1 2 0.979 1.580629177
30 1 1 2 1 0.534 3.247752292 580
30 1 1 2 2 1.06 -1.266351164
30 1 1 3 1 1.094 1.805545041 540
30 1 1 3 2 0.9495 -2.125969178
30 1 2 0 1 1.1785 0 800
30 1 2 0 2 1.1605 0
30 1 2 1 1 1.1325 2.799496965 360
30 1 2 1 2 1.249 3.116610949
30 1 2 2 1 2.704 2.524531004 340
30 1 2 2 2 1.7485 4.312293018
30 1 2 3 1 1.465 0.547518719 420
30 1 2 3 2 1.226 3.229281863
30 1 3 0 1 1.1785 0 800
30 1 3 0 2 1.1605 0
30 1 3 1 1 1.25 2.619803154 380
30 1 3 1 2 1.255 4.408762855
30 1 3 2 1 1.027 6.15577237 220
30 1 3 2 2 1.3175 8.275752482
30 1 3 3 1 1.748 1.10232046 540
30 1 3 3 2 1.2085 -0.140082247
30 1 4 0 1 1.1785 0 800
30 1 4 0 2 1.1605 0
30 1 4 1 1 1.1615 -0.967984852 700
30 1 4 1 2 1.198 4.934545131
30 1 4 2 1 1.334 -0.124891347 860
30 1 4 2 2 1.254 1.703888118
30 1 4 3 1 1.4175 -1.470042851 560
Appendices
163
30 1 4 3 2 1.916 3.775241844
30 2 1 0 1 0.761 0 1080
30 2 1 0 2 0.8395 0
30 2 1 1 1 0.826 2.719390597 120
30 2 1 1 2 0.722 -1.406854144
30 2 1 2 1 0.6965 1.687912497 280
30 2 1 2 2 0.723 -5.951886193
30 2 1 3 1 0.734 -0.08479751 180
30 2 1 3 2 0.757 -1.079245937
30 2 2 0 1 0.761 0 1080
30 2 2 0 2 0.8395 0
30 2 2 1 1 0.689 1.435477601 320
30 2 2 1 2 0.7345 -2.742216142
30 2 2 2 1 1.258 1.687912497 440
30 2 2 2 2 1.156 -0.812695784
30 2 2 3 1 0.882 -0.265023302 660
30 2 2 3 2 0.878 -0.283073342
30 2 3 0 1 0.761 0 1080
30 2 3 0 2 0.8395 0
30 2 3 1 1 0.8325 1.549610474 220
30 2 3 1 2 0.815 -0.991970597
30 2 3 2 1 0.74 4.609501866 80
30 2 3 2 2 0.5415 2.409822491
30 2 3 3 1 0.7755 -0.204324496 160
30 2 3 3 2 0.772 -1.496661481
30 2 4 0 1 0.761 0 1080
30 2 4 0 2 0.8395 0
30 2 4 1 1 0.7615 -1.884167289 380
30 2 4 1 2 0.742 0.312017539
30 2 4 2 1 0.727 0.453300672 340
Appendices
164
30 2 4 2 2 0.734 -0.124400016
30 2 4 3 1 0.7275 -2.561234629 520
30 2 4 3 2 0.7135 0.319174288
31 1 1 0 1 0.665 0 240
31 1 1 0 2 1.092 0
31 1 1 1 1 0.2175 6.685558547 600
31 1 1 1 2 0.585 2.080532274
31 1 1 2 1 0.371 3.246815186 320
31 1 1 2 2 0.6045 0.807092454
31 1 1 3 1 0.724 8.763429259 620
31 1 1 3 2 0.8525 -0.672336259
31 1 2 0 1 0.665 0 240
31 1 2 0 2 1.092 0
31 1 2 1 1 0.526 9.574182091 340
31 1 2 1 2 0.578 2.553114401
31 1 2 2 1 0.572 8.674950748 580
31 1 2 2 2 0.676 3.432408596
31 1 2 3 1 0.5865 10.61341398 440
31 1 2 3 2 0.8565 3.590464898
31 1 3 0 1 0.665 0 240
31 1 3 0 2 1.092 0
31 1 3 1 1 0.3635 8.895006309 500
31 1 3 1 2 0.791 3.803092667
31 1 3 2 1 0.453 10.37203583 740
31 1 3 2 2 0.9025 5.583265721
31 1 3 3 1 0.1275 9.7653075 840
31 1 3 3 2 0.881 1.487312446
31 1 4 0 1 0.665 0 240
31 1 4 0 2 1.092 0
31 1 4 1 1 0.3205 12.34449138 420
Appendices
165
31 1 4 1 2 0.8605 0.741943673
31 1 4 2 1 0.5885 16.07651839 780
31 1 4 2 2 0.8405 3.402447537
31 1 4 3 1 0.3885 12.73759218 260
31 1 4 3 2 0.541 2.961437477
31 2 1 0 1 0.746 0 500
31 2 1 0 2 0.8975 0
31 2 1 1 1 0.6425 -2.768780745 260
31 2 1 1 2 0.7955 -3.335539196
31 2 1 2 1 0.7085 0.239260162 660
31 2 1 2 2 0.8485 -3.8468639
31 2 1 3 1 0.77 4.673745487 400
31 2 1 3 2 0.88 -6.4838045
31 2 2 0 1 0.746 0 500
31 2 2 0 2 0.8975 0
31 2 2 1 1 0.6775 3.979530034 540
31 2 2 1 2 0.802 1.163765233
31 2 2 2 1 0.744 0.49475557 600
31 2 2 2 2 0.836 2.556666526
31 2 2 3 1 0.7505 7.461132936 320
31 2 2 3 2 0.832 1.699164721
31 2 3 0 1 0.746 0 500
31 2 3 0 2 0.8975 0
31 2 3 1 1 0.6585 2.44128522 500
31 2 3 1 2 0.777 0.296467638
31 2 3 2 1 0.7135 -0.779837156 540
31 2 3 2 2 0.7015 1.603232175
31 2 3 3 1 0.6945 5.387774171 580
31 2 3 3 2 0.753 2.000029392
31 2 4 0 1 0.746 0 500
Appendices
166
31 2 4 0 2 0.8975 0
31 2 4 1 1 0.658 3.32901121 700
31 2 4 1 2 0.7665 -1.279037015
31 2 4 2 1 0.7095 -0.779837156 520
31 2 4 2 2 0.76 -0.807029476
31 2 4 3 1 0.664 3.745089691 840
31 2 4 3 2 0.7745 -0.333961787
